Aop:1	Event:142	KeyEvent	KE	"Hyperplasia, Hyperplasia"
Aop:1	Event:334	AdverseOutcome	AO	"Promotion, Hepatocelluar carcinoma"
Aop:1	Event:57	KeyEvent	KE	"Proliferation, Cell proliferation in the absence of cytotoxicity"
Aop:1	Event:294	MolecularInitiatingEvent	MIE	"N/A, Unknown"
Aop:3	Event:887	KeyEvent	KE	"Inhibition, NADH-ubiquinone oxidoreductase  (complex I)"
Aop:3	Event:888	MolecularInitiatingEvent	MIE	"Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)"
Aop:3	Event:177	KeyEvent	KE	"N/A, Mitochondrial dysfunction 1"
Aop:3	Event:889	KeyEvent	KE	"Impaired, Proteostasis"
Aop:3	Event:188	KeyEvent	KE	"N/A, Neuroinflammation"
Aop:3	Event:890	KeyEvent	KE	Degeneration of dopaminergic neurons of the nigrostriatal pathway
Aop:3	Event:896	AdverseOutcome	AO	Parkinsonian motor deficits
Aop:4	Event:103	MolecularInitiatingEvent	MIE	"Activation, Ecdysone receptor"
Aop:4	Event:988	KeyEvent	KE	"Reduction, Release of circulating ecdysis triggering hormone"
Aop:4	Event:990	KeyEvent	KE	"Induction, Incomplete ecdysis"
Aop:4	Event:993	KeyEvent	KE	"Reduction, Abdominal muscle contraction"
Aop:4	Event:351	AdverseOutcome	AO	"Increased, Mortality"
Aop:4	Event:1264	KeyEvent	KE	"Induction, Nuclear receptor E75b gene"
Aop:4	Event:1265	KeyEvent	KE	"Suppression, Fushi tarazu factor-1 gene"
Aop:4	Event:1266	KeyEvent	KE	"Reduction, Release of circulating crustacean cardioactive peptide"
Aop:4	Event:1267	KeyEvent	KE	"Reduction, Ecdysis motoneuron bursts"
Aop:4	Event:1268	KeyEvent	KE	"Reduction, Excitatory postsynaptic potential"
Aop:6	Event:858	KeyEvent	KE	"Decreased, PPARalpha transactivation of gene expression"
Aop:6	Event:860	KeyEvent	KE	"Decreased, Mitochondrial Fatty Acid Beta Oxidation"
Aop:6	Event:861	KeyEvent	KE	"Decreased, Ketogenesis (production of ketone bodies)"
Aop:6	Event:862	KeyEvent	KE	"Not Increased, Circulating Ketone Bodies"
Aop:6	Event:864	AdverseOutcome	AO	"Decreased, Body Weight"
Aop:6	Event:859	KeyEvent	KE	"Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids"
Aop:6	Event:863	KeyEvent	KE	"Increased, Catabolism of Muscle Protein"
Aop:6	Event:998	MolecularInitiatingEvent	MIE	"Binding of antagonist, PPAR alpha"
Aop:6	Event:1000	KeyEvent	KE	"stabilization, PPAR alpha co-repressor"
Aop:7	Event:219	KeyEvent	KE	"Reduction, Plasma 17beta-estradiol concentrations"
Aop:7	Event:3	KeyEvent	KE	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"
Aop:7	Event:406	AdverseOutcome	AO	"impaired, Fertility"
Aop:7	Event:405	AdverseOutcome	AO	"irregularities, ovarian cycle"
Aop:7	Event:408	MolecularInitiatingEvent	MIE	"reduction in ovarian granulosa cells, Aromatase (Cyp19a1)"
Aop:8	Event:239	MolecularInitiatingEvent	MIE	"Activation, Pregnane-X receptor, NR1l2"
Aop:8	Event:319	AdverseOutcome	AO	"Loss, Cochlear function"
Aop:8	Event:280	KeyEvent	KE	Decrease of thyroxine (T4) in neuronal tissue
Aop:8	Event:281	KeyEvent	KE	Decrease of thyroxine (T4) in serum
Aop:8	Event:295	KeyEvent	KE	"Induction, Upregulation of glucuronyltransferase activity"
Aop:8	Event:401	KeyEvent	KE	"Increase, Biliary excretion TH glucuronide"
Aop:8	Event:757	KeyEvent	KE	"Hippocampal anatomy, Altered "
Aop:8	Event:758	KeyEvent	KE	"Hippocampal Physiology, Altered"
Aop:8	Event:756	KeyEvent	KE	"Hippocampal gene expression, Altered "
Aop:10	Event:64	KeyEvent	KE	"Reduction, Ionotropic GABA receptor chloride channel conductance"
Aop:10	Event:616	KeyEvent	KE	"Occurrence, A paroxysmal depolarizing shift"
Aop:10	Event:613	AdverseOutcome	AO	"Occurrence, Epileptic seizure"
Aop:10	Event:667	MolecularInitiatingEvent	MIE	"Binding at picrotoxin site, iGABAR chloride channel"
Aop:10	Event:669	KeyEvent	KE	"Reduction, Neuronal synaptic inhibition"
Aop:10	Event:682	KeyEvent	KE	"Generation, Amplified excitatory postsynaptic potential (EPSP)"
Aop:11	Event:245	MolecularInitiatingEvent	MIE	"Activation, PXR/SXR"
Aop:12	Event:195	KeyEvent	KE	"Inhibition, NMDARs"
Aop:12	Event:352	AdverseOutcome	AO	"N/A, Neurodegeneration"
Aop:12	Event:52	KeyEvent	KE	"Decreased, Calcium influx"
Aop:12	Event:201	MolecularInitiatingEvent	MIE	"Binding of antagonist, NMDA receptors"
Aop:12	Event:381	KeyEvent	KE	Reduced levels of BDNF
Aop:12	Event:55	KeyEvent	KE	"N/A, Cell injury/death"
Aop:12	Event:188	KeyEvent	KE	"N/A, Neuroinflammation"
Aop:12	Event:341	AdverseOutcome	AO	"Impairment, Learning and memory"
Aop:13	Event:201	MolecularInitiatingEvent	MIE	"Binding of antagonist, NMDA receptors"
Aop:13	Event:52	KeyEvent	KE	"Decreased, Calcium influx"
Aop:13	Event:195	KeyEvent	KE	"Inhibition, NMDARs"
Aop:13	Event:341	AdverseOutcome	AO	"Impairment, Learning and memory"
Aop:13	Event:381	KeyEvent	KE	Reduced levels of BDNF
Aop:13	Event:382	KeyEvent	KE	"Aberrant, Dendritic morphology"
Aop:13	Event:385	KeyEvent	KE	Decrease of synaptogenesis
Aop:13	Event:386	KeyEvent	KE	Decrease of neuronal network function
Aop:13	Event:383	KeyEvent	KE	"Reduced, Presynaptic release of glutamate"
Aop:13	Event:55	KeyEvent	KE	"N/A, Cell injury/death"
Aop:14	Event:122	MolecularInitiatingEvent	MIE	"Activation, Glucocorticoid Receptor"
Aop:14	Event:202	KeyEvent	KE	"Inhibition, Nuclear factor kappa B (NF-kB)"
Aop:14	Event:152	KeyEvent	KE	"Suppression, Inflammatory cytokines"
Aop:14	Event:168	KeyEvent	KE	"Decreased, Lymphocytes"
Aop:14	Event:145	KeyEvent	KE	"Induction, IKB inhibitory protein"
Aop:14	Event:323	AdverseOutcome	AO	"Increased, Disease susceptibility"
Aop:14	Event:403	KeyEvent	KE	"Suppression, Immune system"
Aop:15	Event:336	AdverseOutcome	AO	"Increase, Heritable mutations in offspring"
Aop:15	Event:97	MolecularInitiatingEvent	MIE	"Alkylation, DNA"
Aop:15	Event:185	KeyEvent	KE	"Increase, Mutations"
Aop:15	Event:155	KeyEvent	KE	"N/A, Insufficient or incorrect DNA repair"
Aop:16	Event:351	AdverseOutcome	AO	"Increased, Mortality"
Aop:16	Event:442	AdverseOutcome	AO	"Decreased, Population trajectory"
Aop:16	Event:12	MolecularInitiatingEvent	MIE	"Inhibition, Acetylcholinesterase (AchE)"
Aop:16	Event:10	KeyEvent	KE	"Accumulation, Acetylcholine in synapses"
Aop:16	Event:444	KeyEvent	KE	"Increased, Atrioventricular block and bradycardia"
Aop:16	Event:445	KeyEvent	KE	"Increased, Respiratory distress/arrest"
Aop:16	Event:39	KeyEvent	KE	"Induction, Ataxia, paralysis, or hyperactivity"
Aop:17	Event:261	MolecularInitiatingEvent	MIE	"Binding, SH-/selen-proteins"
Aop:17	Event:158	KeyEvent	KE	"N/A, Interferences with SH-/selen-proteins"
Aop:17	Event:130	KeyEvent	KE	"Depletion, GSH"
Aop:17	Event:210	KeyEvent	KE	"N/A, Oxidative stress"
Aop:17	Event:191	KeyEvent	KE	"N/A, Neuronal dysfunction"
Aop:17	Event:188	KeyEvent	KE	"N/A, Neuroinflammation"
Aop:17	Event:352	AdverseOutcome	AO	"N/A, Neurodegeneration"
Aop:18	Event:227	MolecularInitiatingEvent	MIE	"Activation, PPARα"
Aop:18	Event:406	AdverseOutcome	AO	"impaired, Fertility"
Aop:18	Event:266	KeyEvent	KE	"Decrease, Steroidogenic acute regulatory protein (STAR)"
Aop:18	Event:447	KeyEvent	KE	"Reduction, Cholesterol transport in mitochondria"
Aop:18	Event:413	KeyEvent	KE	"Reduction, Testosterone synthesis in Leydig cells"
Aop:18	Event:446	KeyEvent	KE	"Reduction, testosterone level"
Aop:18	Event:289	KeyEvent	KE	"Decrease, Translocator protein (TSPO)"
Aop:18	Event:348	AdverseOutcome	AO	"Malformation, Male reproductive tract"
Aop:19	Event:27	MolecularInitiatingEvent	MIE	"N/A, Androgen receptor, Antagonism"
Aop:19	Event:310	KeyEvent	KE	"Alteration, Wnt pathway"
Aop:19	Event:240	KeyEvent	KE	"Feminisation or incomplete development, Primary and accessory male sex organs"
Aop:19	Event:286	KeyEvent	KE	"Decreased, Transcription of genes by AR"
Aop:19	Event:337	AdverseOutcome	AO	"N/A, Impairment of reproductive capacity"
Aop:21	Event:18	MolecularInitiatingEvent	MIE	"Activation, AhR"
Aop:21	Event:944	KeyEvent	KE	"dimerization, AHR/ARNT"
Aop:21	Event:317	KeyEvent	KE	"Altered, Cardiovascular development/function"
Aop:21	Event:1269	KeyEvent	KE	"Increase, COX-2 expression"
Aop:21	Event:351	AdverseOutcome	AO	"Increased, Mortality"
Aop:21	Event:442	AdverseOutcome	AO	"Decreased, Population trajectory"
Aop:23	Event:360	AdverseOutcome	AO	"Decrease, Population trajectory"
Aop:23	Event:25	MolecularInitiatingEvent	MIE	"Agonism, Androgen receptor"
Aop:23	Event:274	KeyEvent	KE	"Reduction, Testosterone synthesis by ovarian theca cells"
Aop:23	Event:3	KeyEvent	KE	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"
Aop:23	Event:219	KeyEvent	KE	"Reduction, Plasma 17beta-estradiol concentrations"
Aop:23	Event:285	KeyEvent	KE	"Reduction, Vitellogenin synthesis in liver"
Aop:23	Event:78	KeyEvent	KE	"Reduction, Cumulative fecundity and spawning"
Aop:23	Event:221	KeyEvent	KE	"Reduction, Plasma vitellogenin concentrations"
Aop:23	Event:309	KeyEvent	KE	"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"
Aop:23	Event:129	KeyEvent	KE	"Reduction, Gonadotropins, circulating concentrations"
Aop:25	Event:360	AdverseOutcome	AO	"Decrease, Population trajectory"
Aop:25	Event:36	MolecularInitiatingEvent	MIE	"Inhibition, Aromatase"
Aop:25	Event:219	KeyEvent	KE	"Reduction, Plasma 17beta-estradiol concentrations"
Aop:25	Event:285	KeyEvent	KE	"Reduction, Vitellogenin synthesis in liver"
Aop:25	Event:309	KeyEvent	KE	"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"
Aop:25	Event:3	KeyEvent	KE	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"
Aop:25	Event:78	KeyEvent	KE	"Reduction, Cumulative fecundity and spawning"
Aop:25	Event:221	KeyEvent	KE	"Reduction, Plasma vitellogenin concentrations"
Aop:26	Event:51	MolecularInitiatingEvent	MIE	"Inhibition, Ca++ ATPase"
Aop:26	Event:50	KeyEvent	KE	"Increase, Ca++ (intracellular)"
Aop:26	Event:178	KeyEvent	KE	"Disruption, Mitochondrial electron transport chain"
Aop:26	Event:40	KeyEvent	KE	"Decrease, Mitochondrial ATP production"
Aop:26	Event:257	KeyEvent	KE	"Increase, Reactive oxygen species production"
Aop:26	Event:193	KeyEvent	KE	"Decreased, Nitric Oxide"
Aop:26	Event:166	KeyEvent	KE	"Decreased, Long-term potentiation (LTP)"
Aop:26	Event:356	AdverseOutcome	AO	"Increased, Oxidative damage"
Aop:27	Event:41	MolecularInitiatingEvent	MIE	"Inhibition, Bile Salt Export Pump (ABCB11)"
Aop:27	Event:288	KeyEvent	KE	"Activation of specific nuclear receptors, Transcriptional change"
Aop:27	Event:214	KeyEvent	KE	"Bile accumulation, Pathological condition"
Aop:27	Event:87	KeyEvent	KE	"Release, Cytokine"
Aop:27	Event:149	KeyEvent	KE	"Increase, Inflammation"
Aop:27	Event:249	KeyEvent	KE	"Production, Reactive oxygen species"
Aop:27	Event:209	KeyEvent	KE	Peptide Oxidation
Aop:27	Event:357	AdverseOutcome	AO	"Cholestasis, Pathology"
Aop:28	Event:79	MolecularInitiatingEvent	MIE	"Inhibition, Cyclooxygenase activity"
Aop:28	Event:243	KeyEvent	KE	"Reduction, Prostaglandin E2 concentration"
Aop:28	Event:49	KeyEvent	KE	"Reduction, Ca and HCO3 transport to shell gland"
Aop:28	Event:106	KeyEvent	KE	"Reduction, Eggshell thickness"
Aop:28	Event:119	KeyEvent	KE	"N/A, Gap"
Aop:28	Event:253	AdverseOutcome	AO	"N/A, Reproductive failure"
Aop:29	Event:111	MolecularInitiatingEvent	MIE	"Agonism, Estrogen receptor"
Aop:29	Event:78	KeyEvent	KE	"Reduction, Cumulative fecundity and spawning"
Aop:29	Event:220	KeyEvent	KE	"Increase, Plasma vitellogenin concentrations"
Aop:29	Event:307	KeyEvent	KE	"Increase, Vitellogenin synthesis in liver"
Aop:29	Event:252	KeyEvent	KE	"Increase, Renal pathology due to VTG deposition"
Aop:29	Event:360	AdverseOutcome	AO	"Decrease, Population trajectory"
Aop:29	Event:363	AdverseOutcome	AO	"Altered, Reproductive behaviour"
Aop:29	Event:339	AdverseOutcome	AO	"Altered, Larval development"
Aop:29	Event:364	AdverseOutcome	AO	"Impaired development of, Reproductive organs"
Aop:30	Event:360	AdverseOutcome	AO	"Decrease, Population trajectory"
Aop:30	Event:112	MolecularInitiatingEvent	MIE	"Antagonism, Estrogen receptor"
Aop:30	Event:285	KeyEvent	KE	"Reduction, Vitellogenin synthesis in liver"
Aop:30	Event:221	KeyEvent	KE	"Reduction, Plasma vitellogenin concentrations"
Aop:30	Event:309	KeyEvent	KE	"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"
Aop:30	Event:78	KeyEvent	KE	"Reduction, Cumulative fecundity and spawning"
Aop:31	Event:213	MolecularInitiatingEvent	MIE	"N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III)"
Aop:31	Event:21	KeyEvent	KE	"Altered regulation, Alpha hemoglobin"
Aop:31	Event:211	KeyEvent	KE	"Propagation, Oxidative stress"
Aop:31	Event:250	KeyEvent	KE	"Damaging, Red blood cells; hemolysis"
Aop:31	Event:118	KeyEvent	KE	"Formation, Formation of hemoglobin adducts"
Aop:31	Event:131	KeyEvent	KE	"Down Regulation, Gulcose-6-phosphate dehydrogenase"
Aop:31	Event:246	KeyEvent	KE	"Increase, RBC congestion in liver"
Aop:31	Event:161	KeyEvent	KE	"Increase, Liver and splenic hemosiderosis"
Aop:31	Event:173	KeyEvent	KE	"N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number"
Aop:31	Event:321	AdverseOutcome	AO	"N/A, Cyanosis occurs"
Aop:32	Event:77	KeyEvent	KE	"Production, Critical Metabolites (CGA 330050 and CGA 265307)"
Aop:32	Event:164	KeyEvent	KE	"Induction, Liver “Dysfunctional” Changes by CGA 330050"
Aop:32	Event:147	KeyEvent	KE	"Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307"
Aop:32	Event:270	KeyEvent	KE	"Induction, Sustained Hepatotoxicity"
Aop:32	Event:269	KeyEvent	KE	"Induction, Sustained Cell Proliferation"
Aop:32	Event:347	KeyEvent	KE	"Formation, Liver tumor"
Aop:33	Event:9	MolecularInitiatingEvent	MIE	"Activation, 5HT2c"
Aop:33	Event:759	AdverseOutcome	AO	"Increased, Kidney Failure"
Aop:33	Event:294	KeyEvent	KE	"N/A, Unknown"
Aop:34	Event:167	MolecularInitiatingEvent	MIE	"Activation, LXR"
Aop:34	Event:54	KeyEvent	KE	"Up Regulation, CD36"
Aop:34	Event:115	KeyEvent	KE	"Increase, FA Influx"
Aop:34	Event:66	KeyEvent	KE	"Activation, ChREBP"
Aop:34	Event:264	KeyEvent	KE	"Activation, SREBP-1c"
Aop:34	Event:116	KeyEvent	KE	"Activation, FAS"
Aop:34	Event:258	KeyEvent	KE	"Activation, SCD-1"
Aop:34	Event:89	KeyEvent	KE	"Synthesis, De Novo FA"
Aop:34	Event:291	KeyEvent	KE	"Accumulation, Triglyceride"
Aop:34	Event:176	KeyEvent	KE	"Damaging, Mitochondria"
Aop:34	Event:345	AdverseOutcome	AO	"N/A, Liver Steatosis"
Aop:34	Event:228	MolecularInitiatingEvent	MIE	peroxisome proliferator activated receptor promoter demethylation
Aop:35	Event:46	MolecularInitiatingEvent	MIE	"Accumulation, Biological membranes"
Aop:35	Event:169	KeyEvent	KE	"Disruption, Membrane integrity"
Aop:36	Event:231	MolecularInitiatingEvent	MIE	"Decreased, PPAR-alpha activation"
Aop:36	Event:232	MolecularInitiatingEvent	MIE	"Decreased, PPAR-beta activation"
Aop:36	Event:233	MolecularInitiatingEvent	MIE	"Decreased, PPAR-gamma activation"
Aop:36	Event:327	KeyEvent	KE	"Accumulation, Fatty acid"
Aop:36	Event:140	KeyEvent	KE	"Decreased, HSD17B10 expression"
Aop:36	Event:179	KeyEvent	KE	"Decreased, Mitochondrial fatty acid beta-oxidation"
Aop:36	Event:8	KeyEvent	KE	"Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"
Aop:36	Event:459	AdverseOutcome	AO	"Increased, Liver Steatosis"
Aop:37	Event:227	MolecularInitiatingEvent	MIE	"Activation, PPARα"
Aop:37	Event:1170	KeyEvent	KE	"modulation, Genes/proteins that regulate hepatocyte fate"
Aop:37	Event:716	KeyEvent	KE	"Increase, Mitogenic cell proliferation (hepatocytes)"
Aop:37	Event:1171	KeyEvent	KE	"Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci"
Aop:37	Event:719	AdverseOutcome	AO	"Increase, Adenomas/carcinomas (hepatocellular)"
Aop:38	Event:344	AdverseOutcome	AO	"N/A, Liver fibrosis"
Aop:38	Event:244	MolecularInitiatingEvent	MIE	"Alkylation, Protein"
Aop:38	Event:55	KeyEvent	KE	"N/A, Cell injury/death"
Aop:38	Event:134	KeyEvent	KE	"Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)"
Aop:38	Event:276	KeyEvent	KE	"Up Regulation, TGFbeta1 expression"
Aop:38	Event:265	KeyEvent	KE	"Activation, Stellate cells"
Aop:38	Event:68	KeyEvent	KE	"Accumulation, Collagen"
Aop:39	Event:75	MolecularInitiatingEvent	MIE	"N/A, Covalent binding to protein, possibly lysine residue"
Aop:39	Event:151	KeyEvent	KE	"Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways"
Aop:39	Event:313	AdverseOutcome	AO	"Increase, Allergic Respiratory Hypersensitivity Response"
Aop:40	Event:396	MolecularInitiatingEvent	MIE	"Covalent Binding, Protein"
Aop:40	Event:827	AdverseOutcome	AO	"sensitisation, skin"
Aop:40	Event:826	KeyEvent	KE	"Activation, Keratinocytes"
Aop:40	Event:398	KeyEvent	KE	"Activation, Dendritic Cells"
Aop:40	Event:272	KeyEvent	KE	"Activation/Proliferation, T-cells"
Aop:41	Event:139	KeyEvent	KE	"N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects"
Aop:41	Event:165	MolecularInitiatingEvent	MIE	"Activation, Long term AHR receptor driven direct and indirect gene expression changes"
Aop:41	Event:853	KeyEvent	KE	"Changes/Inhibition, Cellular Homeostasis and Apoptosis"
Aop:41	Event:854	KeyEvent	KE	"Alterations, Cellular proliferation / hyperplasia"
Aop:41	Event:856	AdverseOutcome	AO	"Formation, Hepatocellular and Bile duct tumors"
Aop:42	Event:279	MolecularInitiatingEvent	MIE	"Thyroperoxidase, Inhibition"
Aop:42	Event:277	KeyEvent	KE	Decrease of thyroid hormone synthesis
Aop:42	Event:281	KeyEvent	KE	Decrease of thyroxine (T4) in serum
Aop:42	Event:280	KeyEvent	KE	Decrease of thyroxine (T4) in neuronal tissue
Aop:42	Event:402	AdverseOutcome	AO	"Cognitive Function, Decreased "
Aop:42	Event:756	KeyEvent	KE	"Hippocampal gene expression, Altered "
Aop:42	Event:757	KeyEvent	KE	"Hippocampal anatomy, Altered "
Aop:42	Event:758	KeyEvent	KE	"Hippocampal Physiology, Altered"
Aop:43	Event:305	MolecularInitiatingEvent	MIE	"Inhibition, VegfR2"
Aop:43	Event:28	KeyEvent	KE	"Reduction, Angiogenesis"
Aop:43	Event:110	KeyEvent	KE	"Impairment, Endothelial network"
Aop:43	Event:298	KeyEvent	KE	"Insufficiency, Vascular"
Aop:43	Event:1001	AdverseOutcome	AO	"Increased, Developmental Defects"
Aop:46	Event:373	MolecularInitiatingEvent	MIE	"Formation, Pro-mutagenic DNA Adducts"
Aop:46	Event:378	AdverseOutcome	AO	"Tumorigenesis, Hepatocellular carcinoma"
Aop:46	Event:376	KeyEvent	KE	"Increased, Induced Mutations in Critical Genes"
Aop:46	Event:409	KeyEvent	KE	"Metabolism of AFB1, Production of Reactive Electrophiles"
Aop:46	Event:491	KeyEvent	KE	"Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)"
Aop:46	Event:493	KeyEvent	KE	"Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts"
Aop:48	Event:177	KeyEvent	KE	"N/A, Mitochondrial dysfunction 1"
Aop:48	Event:341	AdverseOutcome	AO	"Impairment, Learning and memory"
Aop:48	Event:55	KeyEvent	KE	"N/A, Cell injury/death"
Aop:48	Event:352	KeyEvent	KE	"N/A, Neurodegeneration"
Aop:48	Event:388	KeyEvent	KE	"Overactivation, NMDARs"
Aop:48	Event:389	KeyEvent	KE	"Increased, Intracellular Calcium overload"
Aop:48	Event:618	KeyEvent	KE	"Decreased, Neuronal network function in adult brain"
Aop:48	Event:875	MolecularInitiatingEvent	MIE	"Binding of agonist, Ionotropic glutamate receptors"
Aop:48	Event:188	KeyEvent	KE	"N/A, Neuroinflammation"
Aop:51	Event:406	AdverseOutcome	AO	"impaired, Fertility"
Aop:51	Event:414	KeyEvent	KE	"Increase, Luteinizing hormone (LH) "
Aop:51	Event:415	KeyEvent	KE	"Hyperplasia, Leydig cell"
Aop:51	Event:416	KeyEvent	KE	"Increase proliferation, Leydig cell "
Aop:51	Event:227	MolecularInitiatingEvent	MIE	"Activation, PPARα"
Aop:51	Event:446	KeyEvent	KE	"Reduction, testosterone level"
Aop:51	Event:413	KeyEvent	KE	"Reduction, Testosterone synthesis in Leydig cells"
Aop:51	Event:447	KeyEvent	KE	"Reduction, Cholesterol transport in mitochondria"
Aop:52	Event:111	MolecularInitiatingEvent	MIE	"Agonism, Estrogen receptor"
Aop:52	Event:417	AdverseOutcome	AO	"skewed, sex ratio"
Aop:53	Event:111	MolecularInitiatingEvent	MIE	"Agonism, Estrogen receptor"
Aop:53	Event:418	KeyEvent	KE	"Increased, Vitellogenin synthesis"
Aop:53	Event:220	KeyEvent	KE	"Increase, Plasma vitellogenin concentrations"
Aop:53	Event:419	KeyEvent	KE	"Increased, renal vitellogenin deposition"
Aop:53	Event:421	KeyEvent	KE	"Increased, glomerular rupture and renal hemorrhaging"
Aop:53	Event:422	KeyEvent	KE	"Increased, nephropathy"
Aop:54	Event:425	KeyEvent	KE	Decrease of Thyroidal iodide
Aop:54	Event:280	KeyEvent	KE	Decrease of thyroxine (T4) in neuronal tissue
Aop:54	Event:381	KeyEvent	KE	Reduced levels of BDNF
Aop:54	Event:385	KeyEvent	KE	Decrease of synaptogenesis
Aop:54	Event:341	AdverseOutcome	AO	"Impairment, Learning and memory"
Aop:54	Event:281	KeyEvent	KE	Decrease of thyroxine (T4) in serum
Aop:54	Event:851	KeyEvent	KE	Decrease of GABAergic interneurons
Aop:54	Event:424	MolecularInitiatingEvent	MIE	"Inhibition, Na+/I- symporter (NIS)"
Aop:54	Event:386	KeyEvent	KE	Decrease of neuronal network function
Aop:54	Event:277	KeyEvent	KE	Decrease of thyroid hormone synthesis
Aop:57	Event:18	MolecularInitiatingEvent	MIE	"Activation, AhR"
Aop:57	Event:450	KeyEvent	KE	"Suppression, VLDL secretion"
Aop:57	Event:451	KeyEvent	KE	"Inhibition, Mitochondrial fatty acid beta-oxidation"
Aop:57	Event:327	KeyEvent	KE	"Accumulation, Fatty acid"
Aop:57	Event:216	KeyEvent	KE	"Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)"
Aop:57	Event:291	KeyEvent	KE	"Accumulation, Triglyceride"
Aop:57	Event:455	AdverseOutcome	AO	"Accumulation, Liver lipid"
Aop:57	Event:54	KeyEvent	KE	"Up Regulation, CD36"
Aop:57	Event:465	KeyEvent	KE	"Increased, FA Influx"
Aop:57	Event:466	KeyEvent	KE	"Up Regulation, LDLR (low density lipoprotein receptor)"
Aop:57	Event:467	KeyEvent	KE	"Increased, LDL uptake"
Aop:57	Event:80	KeyEvent	KE	"Up Regulation, CYP1A1"
Aop:57	Event:462	KeyEvent	KE	"Up Regulation, SCD-1"
Aop:58	Event:456	MolecularInitiatingEvent	MIE	"Suppression, Constitutive androstane receptor, NR1l3"
Aop:58	Event:457	KeyEvent	KE	"Activation, SREBF1"
Aop:58	Event:66	KeyEvent	KE	"Activation, ChREBP"
Aop:58	Event:458	KeyEvent	KE	"Increased, De Novo FA synthesis"
Aop:58	Event:459	AdverseOutcome	AO	"Increased, Liver Steatosis"
Aop:58	Event:454	KeyEvent	KE	"Increased, Triglyceride formation"
Aop:58	Event:54	KeyEvent	KE	"Up Regulation, CD36"
Aop:58	Event:462	KeyEvent	KE	"Up Regulation, SCD-1"
Aop:58	Event:463	KeyEvent	KE	"Up Regulation, FAS"
Aop:58	Event:468	MolecularInitiatingEvent	MIE	"Inhibition, PPAR alpha"
Aop:58	Event:167	MolecularInitiatingEvent	MIE	"Activation, LXR"
Aop:58	Event:228	MolecularInitiatingEvent	MIE	peroxisome proliferator activated receptor promoter demethylation
Aop:58	Event:451	KeyEvent	KE	"Inhibition, Mitochondrial fatty acid beta-oxidation"
Aop:58	Event:327	KeyEvent	KE	"Accumulation, Fatty acid"
Aop:58	Event:470	KeyEvent	KE	"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"
Aop:58	Event:465	KeyEvent	KE	"Increased, FA Influx"
Aop:59	Event:461	MolecularInitiatingEvent	MIE	"Suppression, HNF4alpha"
Aop:60	Event:245	MolecularInitiatingEvent	MIE	"Activation, PXR/SXR"
Aop:60	Event:459	AdverseOutcome	AO	"Increased, Liver Steatosis"
Aop:60	Event:471	KeyEvent	KE	"Inhibition, FoxA2"
Aop:60	Event:179	KeyEvent	KE	"Decreased, Mitochondrial fatty acid beta-oxidation"
Aop:60	Event:472	KeyEvent	KE	"Down Regulation, CPT1A"
Aop:60	Event:474	KeyEvent	KE	"Down Regulation, HMGCS2"
Aop:60	Event:462	KeyEvent	KE	"Up Regulation, SCD-1"
Aop:60	Event:54	KeyEvent	KE	"Up Regulation, CD36"
Aop:60	Event:465	KeyEvent	KE	"Increased, FA Influx"
Aop:60	Event:477	KeyEvent	KE	"Decreased, Ketogenesis"
Aop:60	Event:454	KeyEvent	KE	"Increased, Triglyceride formation"
Aop:60	Event:327	KeyEvent	KE	"Accumulation, Fatty acid"
Aop:61	Event:478	MolecularInitiatingEvent	MIE	"Activation, NRF2"
Aop:61	Event:479	MolecularInitiatingEvent	MIE	"Activation, NR1H4"
Aop:61	Event:480	KeyEvent	KE	"Activation, SHP"
Aop:61	Event:227	KeyEvent	KE	"Activation, PPARα"
Aop:61	Event:482	KeyEvent	KE	"Decreased, DHB4/HSD17B4"
Aop:61	Event:451	KeyEvent	KE	"Inhibition, Mitochondrial fatty acid beta-oxidation"
Aop:61	Event:483	KeyEvent	KE	"Activation, LXR alpha"
Aop:61	Event:459	AdverseOutcome	AO	"Increased, Liver Steatosis"
Aop:61	Event:878	KeyEvent	KE	"Inhibition, SREBP1c"
Aop:61	Event:879	KeyEvent	KE	"Activation, MTTP"
Aop:61	Event:880	KeyEvent	KE	"Increased, ApoB100"
Aop:61	Event:881	KeyEvent	KE	"Increased, Triglyceride"
Aop:61	Event:458	KeyEvent	KE	"Increased, De Novo FA synthesis"
Aop:62	Event:484	KeyEvent	KE	"Activation, AKT2"
Aop:62	Event:459	AdverseOutcome	AO	"Increased, Liver Steatosis"
Aop:62	Event:486	MolecularInitiatingEvent	MIE	systemic inflammation leading to hepatic steatosis
Aop:62	Event:457	KeyEvent	KE	"Activation, SREBF1"
Aop:63	Event:675	AdverseOutcome	AO	"Reduced, Reproductive Success"
Aop:63	Event:686	AdverseOutcome	AO	"Declining, Population trajectory"
Aop:63	Event:79	MolecularInitiatingEvent	MIE	"Inhibition, Cyclooxygenase activity"
Aop:63	Event:488	KeyEvent	KE	"Decrease, Ovulation"
Aop:63	Event:685	KeyEvent	KE	"Reduced, Prostaglandins, ovary"
Aop:64	Event:494	MolecularInitiatingEvent	MIE	"Glucocorticoid Receptor Agonist, Activation"
Aop:64	Event:495	KeyEvent	KE	Repressed expression of steroidogenic enzymes 
Aop:64	Event:496	KeyEvent	KE	"Increased apoptosis, decreased number of adult Leydig Cells "
Aop:64	Event:413	KeyEvent	KE	"Reduction, Testosterone synthesis in Leydig cells"
Aop:64	Event:446	KeyEvent	KE	"Reduction, testosterone level"
Aop:64	Event:520	KeyEvent	KE	"Decreased sperm quantity or quality in the adult, Decreased fertility "
Aop:64	Event:406	AdverseOutcome	AO	"impaired, Fertility"
Aop:65	Event:424	MolecularInitiatingEvent	MIE	"Inhibition, Na+/I- symporter (NIS)"
Aop:65	Event:277	KeyEvent	KE	Decrease of thyroid hormone synthesis
Aop:65	Event:281	KeyEvent	KE	Decrease of thyroxine (T4) in serum
Aop:65	Event:280	KeyEvent	KE	Decrease of thyroxine (T4) in neuronal tissue
Aop:65	Event:186	KeyEvent	KE	"Altered, Neuroanatomy"
Aop:65	Event:192	KeyEvent	KE	"Altered, Neurophysiology"
Aop:65	Event:402	AdverseOutcome	AO	"Cognitive Function, Decreased "
Aop:66	Event:505	AdverseOutcome	AO	"Decreased sperm quantity / quality in the adult, Decreased fertility "
Aop:66	Event:653	MolecularInitiatingEvent	MIE	"Decreased testosterone by the fetal Leydig cells, Increased corticosterone"
Aop:66	Event:654	MolecularInitiatingEvent	MIE	"Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid receptor agonists"
Aop:66	Event:655	KeyEvent	KE	"Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells"
Aop:66	Event:656	KeyEvent	KE	"Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells"
Aop:66	Event:657	KeyEvent	KE	"Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells"
Aop:67	Event:505	AdverseOutcome	AO	"Decreased sperm quantity / quality in the adult, Decreased fertility "
Aop:67	Event:658	MolecularInitiatingEvent	MIE	"Decreased testosterone by the fetal Leydig cells, Increased estradiol"
Aop:67	Event:659	MolecularInitiatingEvent	MIE	"Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists"
Aop:67	Event:655	KeyEvent	KE	"Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells"
Aop:67	Event:660	KeyEvent	KE	"decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells"
Aop:67	Event:656	KeyEvent	KE	"Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells"
Aop:68	Event:505	AdverseOutcome	AO	"Decreased sperm quantity / quality in the adult, Decreased fertility "
Aop:68	Event:661	MolecularInitiatingEvent	MIE	"Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome"
Aop:68	Event:655	KeyEvent	KE	"Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells"
Aop:68	Event:657	KeyEvent	KE	"Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells"
Aop:68	Event:656	KeyEvent	KE	"Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells"
Aop:69	Event:642	MolecularInitiatingEvent	MIE	"Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol"
Aop:69	Event:643	MolecularInitiatingEvent	MIE	"Decreased Cholesterol, Decreased Uptake of Lipoproteins"
Aop:69	Event:644	MolecularInitiatingEvent	MIE	"Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membrane"
Aop:69	Event:645	KeyEvent	KE	"Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells"
Aop:69	Event:646	AdverseOutcome	AO	"Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis"
Aop:70	Event:520	AdverseOutcome	AO	"Decreased sperm quantity or quality in the adult, Decreased fertility "
Aop:70	Event:640	MolecularInitiatingEvent	MIE	"Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell"
Aop:70	Event:647	KeyEvent	KE	"Decreased steroidogenesis, Decreased Activity of Steroidogenic Enzymes in Adult Leydig cells"
Aop:70	Event:648	KeyEvent	KE	"Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells"
Aop:70	Event:649	KeyEvent	KE	"Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton"
Aop:71	Event:525	KeyEvent	KE	"Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells"
Aop:71	Event:520	AdverseOutcome	AO	"Decreased sperm quantity or quality in the adult, Decreased fertility "
Aop:71	Event:650	MolecularInitiatingEvent	MIE	"Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid"
Aop:71	Event:651	KeyEvent	KE	"Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testosterone by adult Leydig cells"
Aop:71	Event:652	KeyEvent	KE	"Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig cells"
Aop:72	Event:228	MolecularInitiatingEvent	MIE	peroxisome proliferator activated receptor promoter demethylation
Aop:72	Event:1028	KeyEvent	KE	"Activation of specific nuclear receptors, PPAR-gamma activation"
Aop:72	Event:1447	AdverseOutcome	AO	obesity
Aop:72	Event:1448	KeyEvent	KE	activation of CCAAT/enhancer-binding protein alpha
Aop:72	Event:1449	KeyEvent	KE	increased adipogenesis
Aop:72	Event:1450	KeyEvent	KE	decreased dopamine
Aop:72	Event:1451	KeyEvent	KE	decreased reward
Aop:72	Event:1452	KeyEvent	KE	decreased DNA methylation of tyrosine hydroxylase
Aop:72	Event:1453	KeyEvent	KE	decreased methylation of dopamine transporter promoter
Aop:72	Event:1454	MolecularInitiatingEvent	MIE	chronic high fat diet
Aop:73	Event:526	MolecularInitiatingEvent	MIE	"Inhibition, Inhibition of Dopamine-beta-hydroxylase"
Aop:73	Event:527	AdverseOutcome	AO	"Decreased, Decreased fecundity "
Aop:73	Event:528	KeyEvent	KE	"Decreased, Synthesis of NE"
Aop:73	Event:529	KeyEvent	KE	"Decreased, GnRH cfos activity"
Aop:73	Event:530	KeyEvent	KE	"Decreased, GnRH pulsatility/release"
Aop:73	Event:531	KeyEvent	KE	"Decreased, LH Surge"
Aop:73	Event:532	KeyEvent	KE	"Delayed, Ovulation"
Aop:73	Event:533	KeyEvent	KE	"Decreased, Cortical granule release/distribution upon fertilization"
Aop:73	Event:534	KeyEvent	KE	"Altered, Formation of cortical envelope"
Aop:73	Event:535	KeyEvent	KE	"Abnormal, Sperm penetration (polyspermy)"
Aop:73	Event:536	KeyEvent	KE	"Altered, Chromosome number (polyploid) zygote"
Aop:74	Event:543	AdverseOutcome	AO	"Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult testis"
Aop:74	Event:662	MolecularInitiatingEvent	MIE	"Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis"
Aop:74	Event:655	KeyEvent	KE	"Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells"
Aop:74	Event:540	KeyEvent	KE	"Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells"
Aop:74	Event:541	KeyEvent	KE	"Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells"
Aop:77	Event:559	MolecularInitiatingEvent	MIE	"Activation, Nicotinic acetylcholine receptor"
Aop:77	Event:177	KeyEvent	KE	"N/A, Mitochondrial dysfunction 1"
Aop:77	Event:341	KeyEvent	KE	"Impairment, Learning and memory"
Aop:77	Event:560	KeyEvent	KE	"Abnormal, Foraging activity and behavior"
Aop:77	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:77	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:77	Event:1243	KeyEvent	KE	"Altered, Ca2+-calmodulin activated signal transduction"
Aop:78	Event:559	MolecularInitiatingEvent	MIE	"Activation, Nicotinic acetylcholine receptor"
Aop:78	Event:177	KeyEvent	KE	"N/A, Mitochondrial dysfunction 1"
Aop:78	Event:386	KeyEvent	KE	Decrease of neuronal network function
Aop:78	Event:341	KeyEvent	KE	"Impairment, Learning and memory"
Aop:78	Event:564	KeyEvent	KE	"Abnormal, Roll change within caste"
Aop:78	Event:565	KeyEvent	KE	"Reduced, Brood care"
Aop:78	Event:566	AdverseOutcome	AO	"impaired, Larval development"
Aop:78	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:79	Event:559	MolecularInitiatingEvent	MIE	"Activation, Nicotinic acetylcholine receptor"
Aop:79	Event:177	KeyEvent	KE	"N/A, Mitochondrial dysfunction 1"
Aop:79	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:79	Event:568	KeyEvent	KE	"impaired, Hive thermoregulation"
Aop:79	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:80	Event:177	KeyEvent	KE	"N/A, Mitochondrial dysfunction 1"
Aop:80	Event:570	KeyEvent	KE	"Accumulation, Damaged mitochondrial DNA"
Aop:80	Event:571	KeyEvent	KE	"Accelerated, Aging"
Aop:80	Event:572	AdverseOutcome	AO	"Decrease, Number of worker bees"
Aop:80	Event:568	AdverseOutcome	AO	"impaired, Hive thermoregulation"
Aop:80	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:80	Event:664	KeyEvent	KE	"Overwhelmed, Mitochondrial DNA repair mechanisms"
Aop:80	Event:559	MolecularInitiatingEvent	MIE	"Activation, Nicotinic acetylcholine receptor"
Aop:81	Event:573	KeyEvent	KE	"Increase, Energetic demands and therefore metabolic stress"
Aop:81	Event:574	KeyEvent	KE	"Increased, Appetite and hunger"
Aop:81	Event:560	KeyEvent	KE	"Abnormal, Foraging activity and behavior"
Aop:81	Event:572	AdverseOutcome	AO	"Decrease, Number of worker bees"
Aop:81	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:82	Event:564	KeyEvent	KE	"Abnormal, Roll change within caste"
Aop:82	Event:565	KeyEvent	KE	"Reduced, Brood care"
Aop:82	Event:566	AdverseOutcome	AO	"impaired, Larval development"
Aop:82	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:84	Event:403	KeyEvent	KE	"Suppression, Immune system"
Aop:84	Event:576	KeyEvent	KE	"Increased, Viral susceptibility"
Aop:84	Event:577	KeyEvent	KE	"impaired, Development"
Aop:84	Event:572	AdverseOutcome	AO	"Decrease, Number of worker bees"
Aop:84	Event:568	AdverseOutcome	AO	"impaired, Hive thermoregulation"
Aop:84	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:85	Event:403	KeyEvent	KE	"Suppression, Immune system"
Aop:85	Event:576	KeyEvent	KE	"Increased, Viral susceptibility"
Aop:85	Event:560	KeyEvent	KE	"Abnormal, Foraging activity and behavior"
Aop:85	Event:572	AdverseOutcome	AO	"Decrease, Number of worker bees"
Aop:85	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:86	Event:578	KeyEvent	KE	"Decreased, Glucose oxidase enzyme activity"
Aop:86	Event:579	KeyEvent	KE	"Decreased, Hydrogen peroxide production"
Aop:86	Event:580	KeyEvent	KE	"Reduced, Antiseptic incorporated in food"
Aop:86	Event:564	KeyEvent	KE	"Abnormal, Roll change within caste"
Aop:86	Event:561	KeyEvent	KE	"Reduced, Food storage"
Aop:86	Event:566	AdverseOutcome	AO	"impaired, Larval development"
Aop:86	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:87	Event:559	MolecularInitiatingEvent	MIE	"Activation, Nicotinic acetylcholine receptor"
Aop:87	Event:177	KeyEvent	KE	"N/A, Mitochondrial dysfunction 1"
Aop:87	Event:341	KeyEvent	KE	"Impairment, Learning and memory"
Aop:87	Event:560	KeyEvent	KE	"Abnormal, Foraging activity and behavior"
Aop:87	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:87	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:87	Event:1108	KeyEvent	KE	"Abnormal, Role change within caste"
Aop:87	Event:1243	KeyEvent	KE	"Altered, Ca2+-calmodulin activated signal transduction"
Aop:88	Event:559	MolecularInitiatingEvent	MIE	"Activation, Nicotinic acetylcholine receptor"
Aop:88	Event:341	KeyEvent	KE	"Impairment, Learning and memory"
Aop:88	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:88	Event:560	KeyEvent	KE	"Abnormal, Foraging activity and behavior"
Aop:88	Event:663	KeyEvent	KE	"Desensitization, Nicotinic acetylcholine receptor"
Aop:88	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:88	Event:1243	KeyEvent	KE	"Altered, Ca2+-calmodulin activated signal transduction"
Aop:89	Event:559	MolecularInitiatingEvent	MIE	"Activation, Nicotinic acetylcholine receptor"
Aop:89	Event:341	KeyEvent	KE	"Impairment, Learning and memory"
Aop:89	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:89	Event:560	KeyEvent	KE	"Abnormal, Foraging activity and behavior"
Aop:89	Event:663	KeyEvent	KE	"Desensitization, Nicotinic acetylcholine receptor"
Aop:89	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:89	Event:1108	KeyEvent	KE	"Abnormal, Role change within caste"
Aop:89	Event:1243	KeyEvent	KE	"Altered, Ca2+-calmodulin activated signal transduction"
Aop:90	Event:559	MolecularInitiatingEvent	MIE	"Activation, Nicotinic acetylcholine receptor"
Aop:90	Event:341	KeyEvent	KE	"Impairment, Learning and memory"
Aop:90	Event:564	KeyEvent	KE	"Abnormal, Roll change within caste"
Aop:90	Event:565	KeyEvent	KE	"Reduced, Brood care"
Aop:90	Event:566	AdverseOutcome	AO	"impaired, Larval development"
Aop:90	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:90	Event:663	KeyEvent	KE	"Desensitization, Nicotinic acetylcholine receptor"
Aop:90	Event:386	KeyEvent	KE	Decrease of neuronal network function
Aop:91	Event:584	MolecularInitiatingEvent	MIE	"Inhibition, sodium channel"
Aop:91	Event:585	KeyEvent	KE	"Decreased, Sodium conductance 1"
Aop:91	Event:586	KeyEvent	KE	"Reduced, swimming speed"
Aop:91	Event:587	AdverseOutcome	AO	"Reduced, feeding 1"
Aop:91	Event:588	AdverseOutcome	AO	"Increased, predation"
Aop:91	Event:592	AdverseOutcome	AO	"Reduced, survival"
Aop:93	Event:585	KeyEvent	KE	"Decreased, Sodium conductance 1"
Aop:93	Event:586	KeyEvent	KE	"Reduced, swimming speed"
Aop:93	Event:588	AdverseOutcome	AO	"Increased, predation"
Aop:93	Event:584	MolecularInitiatingEvent	MIE	"Inhibition, sodium channel"
Aop:94	Event:584	MolecularInitiatingEvent	MIE	"Inhibition, sodium channel"
Aop:94	Event:444	KeyEvent	KE	"Increased, Atrioventricular block and bradycardia"
Aop:94	Event:445	KeyEvent	KE	"Increased, Respiratory distress/arrest"
Aop:94	Event:590	KeyEvent	KE	"N/A, hypoxia"
Aop:94	Event:591	AdverseOutcome	AO	"Increased, amputations"
Aop:94	Event:585	KeyEvent	KE	"Decreased, Sodium conductance 1"
Aop:95	Event:585	KeyEvent	KE	"Decreased, Sodium conductance 1"
Aop:95	Event:586	KeyEvent	KE	"Reduced, swimming speed"
Aop:95	Event:587	KeyEvent	KE	"Reduced, feeding 1"
Aop:95	Event:588	KeyEvent	KE	"Increased, predation"
Aop:95	Event:592	AdverseOutcome	AO	"Reduced, survival"
Aop:95	Event:593	MolecularInitiatingEvent	MIE	"Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel "
Aop:96	Event:598	MolecularInitiatingEvent	MIE	"modulation, sodium channel"
Aop:96	Event:599	KeyEvent	KE	"prolonged, Depolarization of neuronal membrane"
Aop:96	Event:600	KeyEvent	KE	"Overactivation, Neuronotransmitter release"
Aop:96	Event:601	KeyEvent	KE	"Overactivation, muscle contraction"
Aop:96	Event:602	KeyEvent	KE	"Increased, Ataxia, paralysis, or hyperactivity"
Aop:96	Event:351	AdverseOutcome	AO	"Increased, Mortality"
Aop:97	Event:619	MolecularInitiatingEvent	MIE	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"
Aop:97	Event:623	AdverseOutcome	AO	"Increase, predation"
Aop:97	Event:625	KeyEvent	KE	"Increased, muscular waves in foot"
Aop:97	Event:1139	KeyEvent	KE	"Increased, water retention in foot"
Aop:97	Event:361	AdverseOutcome	AO	"Decline, Population"
Aop:97	Event:1142	KeyEvent	KE	"Increased, valve movement"
Aop:97	Event:1143	KeyEvent	KE	"Depletion, energy reserves"
Aop:97	Event:624	KeyEvent	KE	"Increased, foot detachment"
Aop:97	Event:622	KeyEvent	KE	"Increased, locomotion"
Aop:97	Event:626	KeyEvent	KE	"Increased, serotonin (5-HT) "
Aop:98	Event:619	MolecularInitiatingEvent	MIE	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"
Aop:98	Event:626	KeyEvent	KE	"Increased, serotonin (5-HT) "
Aop:98	Event:627	KeyEvent	KE	"Decreased, anxiety"
Aop:98	Event:629	KeyEvent	KE	"Decreased, sheltering"
Aop:98	Event:588	AdverseOutcome	AO	"Increased, predation"
Aop:99	Event:633	KeyEvent	KE	"Decrease, histaminergic neuron excitation"
Aop:99	Event:634	KeyEvent	KE	"N/A, sedation"
Aop:99	Event:635	KeyEvent	KE	"Decreased, locomotion"
Aop:99	Event:636	AdverseOutcome	AO	"Decreased, survival"
Aop:99	Event:588	AdverseOutcome	AO	"Increased, predation"
Aop:99	Event:638	MolecularInitiatingEvent	MIE	"Antagonism, Histamine Receptor (H2)"
Aop:99	Event:341	KeyEvent	KE	"Impairment, Learning and memory"
Aop:100	Event:79	MolecularInitiatingEvent	MIE	"Inhibition, Cyclooxygenase activity"
Aop:100	Event:671	KeyEvent	KE	"Reduced, Prostaglandin F2alpha concentration, plasma "
Aop:100	Event:672	KeyEvent	KE	"Reduced, Prostaglandin F2alpha synthesis, ovary  "
Aop:100	Event:673	KeyEvent	KE	"Reduced, Spawning behavior"
Aop:100	Event:674	KeyEvent	KE	"Reduced, Ability to attract spawning mates"
Aop:100	Event:675	AdverseOutcome	AO	"Reduced, Reproductive Success"
Aop:100	Event:360	AdverseOutcome	AO	"Decrease, Population trajectory"
Aop:101	Event:79	MolecularInitiatingEvent	MIE	"Inhibition, Cyclooxygenase activity"
Aop:101	Event:674	KeyEvent	KE	"Reduced, Ability to attract spawning mates"
Aop:101	Event:675	AdverseOutcome	AO	"Reduced, Reproductive Success"
Aop:101	Event:679	AdverseOutcome	AO	"Decline, Population trajectory"
Aop:101	Event:678	KeyEvent	KE	"Reduced, Pheromone release"
Aop:101	Event:681	KeyEvent	KE	"Decreased, Prostaglandin F2alpha synthesis, ovary  "
Aop:101	Event:671	KeyEvent	KE	"Reduced, Prostaglandin F2alpha concentration, plasma "
Aop:102	Event:687	KeyEvent	KE	"Reduced, Prostaglandin E2 concentration, hypothalamus"
Aop:102	Event:689	KeyEvent	KE	"Reduced, Gonadotropin releasing hormone, hypothalamus"
Aop:102	Event:690	KeyEvent	KE	"Reduced, Luteinizing hormone (LH), plasma "
Aop:102	Event:691	KeyEvent	KE	"Reduced, Maturation inducing steroid, plasma"
Aop:102	Event:692	KeyEvent	KE	"Reduced, Maturation inducing steroid receptor signalling, oocyte"
Aop:102	Event:694	KeyEvent	KE	"Reduced, Meiotic prophase I/metaphase I transition, oocyte"
Aop:102	Event:693	KeyEvent	KE	"Increased, cyclic adenosine monophosphate"
Aop:102	Event:679	AdverseOutcome	AO	"Decline, Population trajectory"
Aop:102	Event:675	AdverseOutcome	AO	"Reduced, Reproductive Success"
Aop:102	Event:79	MolecularInitiatingEvent	MIE	"Inhibition, Cyclooxygenase activity"
Aop:103	Event:79	MolecularInitiatingEvent	MIE	"Inhibition, Cyclooxygenase activity"
Aop:103	Event:687	KeyEvent	KE	"Reduced, Prostaglandin E2 concentration, hypothalamus"
Aop:103	Event:689	KeyEvent	KE	"Reduced, Gonadotropin releasing hormone, hypothalamus"
Aop:103	Event:690	KeyEvent	KE	"Reduced, Luteinizing hormone (LH), plasma "
Aop:103	Event:691	KeyEvent	KE	"Reduced, Maturation inducing steroid, plasma"
Aop:103	Event:692	KeyEvent	KE	"Reduced, Maturation inducing steroid receptor signalling, oocyte"
Aop:103	Event:695	KeyEvent	KE	"Upregulated, Spindle assembly checkpoint protein Mad2-oocyte"
Aop:103	Event:696	KeyEvent	KE	"Increased, Chromosome misseggregation"
Aop:103	Event:675	AdverseOutcome	AO	"Reduced, Reproductive Success"
Aop:103	Event:686	AdverseOutcome	AO	"Declining, Population trajectory"
Aop:104	Event:697	MolecularInitiatingEvent	MIE	"impaired, ion channels"
Aop:104	Event:351	AdverseOutcome	AO	"Increased, Mortality"
Aop:104	Event:698	KeyEvent	KE	"Altered, Action Potential"
Aop:104	Event:699	KeyEvent	KE	"Increased, cardiac arrthymia"
Aop:105	Event:708	KeyEvent	KE	"Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)"
Aop:105	Event:709	KeyEvent	KE	"Increase, Cytotoxicity (renal tubular cell)"
Aop:105	Event:710	KeyEvent	KE	"Increase, Regenerative cell proliferation (tubular epithelial cells)"
Aop:105	Event:713	AdverseOutcome	AO	"Increase, Adenomas/carcinomas (renal tubular)"
Aop:105	Event:767	KeyEvent	KE	"Increase, Hyperplasia (renal tubular cells)"
Aop:105	Event:714	MolecularInitiatingEvent	MIE	"Increased, Binding of chemicals to 2u (serum)"
Aop:106	Event:718	MolecularInitiatingEvent	MIE	"Binding, Tubulin"
Aop:106	Event:720	KeyEvent	KE	"Depolymerization, Microtubule"
Aop:106	Event:721	KeyEvent	KE	"Disorganization, Spindle"
Aop:106	Event:728	AdverseOutcome	AO	"Increase, Aneuploid offspring"
Aop:106	Event:752	KeyEvent	KE	"Altered, Meiotic chromosome dynamics"
Aop:106	Event:723	KeyEvent	KE	"Altered, Chromosome number"
Aop:107	Event:715	MolecularInitiatingEvent	MIE	"Activation, Constitutive androstane receptor"
Aop:107	Event:716	KeyEvent	KE	"Increase, Mitogenic cell proliferation (hepatocytes)"
Aop:107	Event:719	AdverseOutcome	AO	"Increase, Adenomas/carcinomas (hepatocellular)"
Aop:107	Event:774	KeyEvent	KE	"Increase, Preneoplastic foci (hepatocytes)"
Aop:107	Event:1214	KeyEvent	KE	"Altered gene expression specific to CAR activation, Hepatocytes"
Aop:108	Event:719	AdverseOutcome	AO	"Increase, Adenomas/carcinomas (hepatocellular)"
Aop:108	Event:768	KeyEvent	KE	"Increase, Cytotoxicity"
Aop:108	Event:209	KeyEvent	KE	Peptide Oxidation
Aop:108	Event:726	KeyEvent	KE	"Increased, Induction of pyruvate dehydrogenase (PDH)"
Aop:108	Event:724	MolecularInitiatingEvent	MIE	"Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme"
Aop:108	Event:769	KeyEvent	KE	"Increase, Oxidative metabolism"
Aop:109	Event:733	KeyEvent	KE	"Increase, Necrosis (terminal bronchiolar cells)"
Aop:109	Event:734	KeyEvent	KE	"Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)"
Aop:109	Event:735	KeyEvent	KE	"Increase, Hyperplasia (terminal bronchiolar cells)"
Aop:109	Event:736	AdverseOutcome	AO	"Increase, Adenomas/carcinomas (bronchioloalveolar)"
Aop:109	Event:770	MolecularInitiatingEvent	MIE	"Increase, Cytotoxicity (club cells)"
Aop:110	Event:737	MolecularInitiatingEvent	MIE	"Decreased, Uptake of inorganic iodide"
Aop:110	Event:739	KeyEvent	KE	"Increase, Hypertrophy and proliferation (follicular cell)"
Aop:110	Event:740	KeyEvent	KE	"Increase, Hyperplasia (follicular cells)"
Aop:110	Event:741	AdverseOutcome	AO	"Increase, Adenomas/carcinomas (follicular cell)"
Aop:110	Event:753	KeyEvent	KE	"Increase, Thyroid-stimulating hormone (TSH)"
Aop:110	Event:771	KeyEvent	KE	"Decrease, Serum thyroid hormone (T4/T3)"
Aop:111	Event:742	MolecularInitiatingEvent	MIE	"Decreased, Androgen receptor activity"
Aop:111	Event:743	KeyEvent	KE	"Decreased, Testosterone binding to androgen receptor (hypothalamus)"
Aop:111	Event:744	KeyEvent	KE	"Increase, Hyperplasia (Leydig cells)"
Aop:111	Event:745	AdverseOutcome	AO	"Increase, Leydig cell tumors"
Aop:111	Event:754	KeyEvent	KE	"Increased, Luteinizing hormone (LH) "
Aop:112	Event:746	MolecularInitiatingEvent	MIE	"Increase, Dopaminergic activity"
Aop:112	Event:747	KeyEvent	KE	"Decreased, Prolactin"
Aop:112	Event:748	KeyEvent	KE	"Increased, Estrogen receptor (ER) activity"
Aop:112	Event:749	KeyEvent	KE	"Decreased, Progesterone from corpus luteum"
Aop:112	Event:772	KeyEvent	KE	"Increase, Hyperplasia (glandular epithelial cells of endometrium)"
Aop:112	Event:773	AdverseOutcome	AO	"Increase, Endometrial adenocarcinomas"
Aop:113	Event:760	MolecularInitiatingEvent	MIE	"Activation, Glutamate-gated chloride channel"
Aop:113	Event:761	KeyEvent	KE	"Increased, Chloride conductance"
Aop:113	Event:763	KeyEvent	KE	"hyperpolarisation, neuron"
Aop:113	Event:764	KeyEvent	KE	"N/A, Ataxia, paralysis, or hyperactivity"
Aop:113	Event:351	AdverseOutcome	AO	"Increased, Mortality"
Aop:113	Event:765	AdverseOutcome	AO	"Decreased, population 1"
Aop:114	Event:766	MolecularInitiatingEvent	MIE	"Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme"
Aop:114	Event:775	KeyEvent	KE	"Increased, Plasma tyrosine"
Aop:114	Event:776	KeyEvent	KE	"Increase, Cytotoxicity (corneal cells)"
Aop:114	Event:777	KeyEvent	KE	"Increase, Inflammation (corneal cells)"
Aop:114	Event:778	KeyEvent	KE	"Increase, Regenerative cell proliferation (corneal cells)"
Aop:114	Event:779	AdverseOutcome	AO	"Increase, Papillomas/carcinomas (squamous cells)"
Aop:115	Event:780	MolecularInitiatingEvent	MIE	"Increase, Cytotoxicity (epithelial cells)"
Aop:115	Event:149	KeyEvent	KE	"Increase, Inflammation"
Aop:115	Event:781	KeyEvent	KE	"Increase, Regenerative cell proliferation (forestomach epithelial cells)"
Aop:115	Event:782	KeyEvent	KE	"Increase, Hyperplasia (forestomach epithelial cells)"
Aop:115	Event:779	AdverseOutcome	AO	"Increase, Papillomas/carcinomas (squamous cells)"
Aop:116	Event:783	MolecularInitiatingEvent	MIE	"Increase, Cytotoxicity (tubular epithelial cells)"
Aop:116	Event:710	KeyEvent	KE	"Increase, Regenerative cell proliferation (tubular epithelial cells)"
Aop:116	Event:784	KeyEvent	KE	"Increase, Hyperplasia (tubular epithelial cells)"
Aop:116	Event:713	AdverseOutcome	AO	"Increase, Adenomas/carcinomas (renal tubular)"
Aop:117	Event:785	MolecularInitiatingEvent	MIE	"Activation, Androgen receptor"
Aop:117	Event:716	KeyEvent	KE	"Increase, Mitogenic cell proliferation (hepatocytes)"
Aop:117	Event:774	KeyEvent	KE	"Increase, Preneoplastic foci (hepatocytes)"
Aop:117	Event:719	AdverseOutcome	AO	"Increase, Adenomas/carcinomas (hepatocellular)"
Aop:118	Event:786	MolecularInitiatingEvent	MIE	"Increase, Cytotoxicity (hepatocytes)"
Aop:118	Event:787	KeyEvent	KE	"Increase, Regenerative cell proliferation (hepatocytes)"
Aop:118	Event:774	KeyEvent	KE	"Increase, Preneoplastic foci (hepatocytes)"
Aop:118	Event:719	AdverseOutcome	AO	"Increase, Adenomas/carcinomas (hepatocellular)"
Aop:119	Event:279	MolecularInitiatingEvent	MIE	"Thyroperoxidase, Inhibition"
Aop:119	Event:788	KeyEvent	KE	"Decrease, Incorporation of active iodide into iodotyrosines"
Aop:119	Event:739	KeyEvent	KE	"Increase, Hypertrophy and proliferation (follicular cell)"
Aop:119	Event:740	KeyEvent	KE	"Increase, Hyperplasia (follicular cells)"
Aop:119	Event:753	KeyEvent	KE	"Increase, Thyroid-stimulating hormone (TSH)"
Aop:119	Event:741	AdverseOutcome	AO	"Increase, Adenomas/carcinomas (follicular cell)"
Aop:119	Event:771	KeyEvent	KE	"Decrease, Serum thyroid hormone (T4/T3)"
Aop:120	Event:790	MolecularInitiatingEvent	MIE	"Inhibition, 5α-reductase activity"
Aop:120	Event:791	KeyEvent	KE	"Increased, Leutinizing hormone (LH)"
Aop:120	Event:744	KeyEvent	KE	"Increase, Hyperplasia (Leydig cells)"
Aop:120	Event:792	KeyEvent	KE	"Decrease, Bioactivation of testosterone"
Aop:120	Event:745	AdverseOutcome	AO	"Increase, Leydig cell tumors"
Aop:121	Event:793	MolecularInitiatingEvent	MIE	"Increase, Urinary bladder calculi"
Aop:121	Event:794	KeyEvent	KE	"Increase, Cytotoxicity (urothelial cells)"
Aop:121	Event:795	KeyEvent	KE	"Increase, Regenerative cell proliferation (urothelial cells)"
Aop:121	Event:796	KeyEvent	KE	"Increase, Hyperplasia (urothelial)"
Aop:121	Event:797	AdverseOutcome	AO	"Increase, Adenomas/carcinomas (urothelial)"
Aop:122	Event:798	MolecularInitiatingEvent	MIE	"Inhibition, Prolyl hydroxylases"
Aop:122	Event:799	KeyEvent	KE	"Increased, HIF-1 heterodimer"
Aop:122	Event:800	KeyEvent	KE	"Decreased, Aromatase (Cyp19a1) mRNA"
Aop:122	Event:3	KeyEvent	KE	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"
Aop:122	Event:219	KeyEvent	KE	"Reduction, Plasma 17beta-estradiol concentrations"
Aop:122	Event:285	KeyEvent	KE	"Reduction, Vitellogenin synthesis in liver"
Aop:122	Event:221	KeyEvent	KE	"Reduction, Plasma vitellogenin concentrations"
Aop:122	Event:309	KeyEvent	KE	"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"
Aop:122	Event:78	AdverseOutcome	AO	"Reduction, Cumulative fecundity and spawning"
Aop:122	Event:360	AdverseOutcome	AO	"Decrease, Population trajectory"
Aop:123	Event:801	MolecularInitiatingEvent	MIE	"modulation, Unknown"
Aop:123	Event:799	KeyEvent	KE	"Increased, HIF-1 heterodimer"
Aop:123	Event:802	KeyEvent	KE	"Increased, HIF-1 alpha transcription"
Aop:123	Event:800	KeyEvent	KE	"Decreased, Aromatase (Cyp19a1) mRNA"
Aop:123	Event:219	KeyEvent	KE	"Reduction, Plasma 17beta-estradiol concentrations"
Aop:123	Event:3	KeyEvent	KE	"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"
Aop:123	Event:285	KeyEvent	KE	"Reduction, Vitellogenin synthesis in liver"
Aop:123	Event:221	KeyEvent	KE	"Reduction, Plasma vitellogenin concentrations"
Aop:123	Event:309	KeyEvent	KE	"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"
Aop:123	Event:78	AdverseOutcome	AO	"Reduction, Cumulative fecundity and spawning"
Aop:123	Event:360	AdverseOutcome	AO	"Decrease, Population trajectory"
Aop:124	Event:804	MolecularInitiatingEvent	MIE	"Inhibition, HMG-CoA reductase"
Aop:124	Event:805	KeyEvent	KE	"Decreased, mevalonate"
Aop:124	Event:807	KeyEvent	KE	"Decreased, cholesterol"
Aop:124	Event:808	KeyEvent	KE	"Decreased, Testosterone"
Aop:124	Event:809	KeyEvent	KE	"malformed, Male reproductive tract"
Aop:124	Event:330	AdverseOutcome	AO	"Decrease, Fertility"
Aop:126	Event:848	KeyEvent	KE	"Decreased, Binding of NE to NE receptors on GnRH neurons"
Aop:126	Event:849	MolecularInitiatingEvent	MIE	"Inhibition, Antgonism of NE receptor"
Aop:126	Event:529	KeyEvent	KE	"Decreased, GnRH cfos activity"
Aop:126	Event:530	KeyEvent	KE	"Decreased, GnRH pulsatility/release"
Aop:126	Event:531	KeyEvent	KE	"Decreased, LH Surge"
Aop:126	Event:532	KeyEvent	KE	"Delayed, Ovulation"
Aop:126	Event:533	KeyEvent	KE	"Decreased, Cortical granule release/distribution upon fertilization"
Aop:126	Event:534	KeyEvent	KE	"Altered, Formation of cortical envelope"
Aop:126	Event:535	KeyEvent	KE	"Abnormal, Sperm penetration (polyspermy)"
Aop:126	Event:536	KeyEvent	KE	"Altered, Chromosome number (polyploid) zygote"
Aop:126	Event:527	AdverseOutcome	AO	"Decreased, Decreased fecundity "
Aop:128	Event:277	MolecularInitiatingEvent	MIE	Decrease of thyroid hormone synthesis
Aop:128	Event:426	KeyEvent	KE	"Decreased, Thyroxine (T4) in serum"
Aop:128	Event:814	AdverseOutcome	AO	"Occurrence, Kidney toxicity"
Aop:128	Event:819	KeyEvent	KE	"Decreased, Glomerular filtration"
Aop:128	Event:820	KeyEvent	KE	"Decreased, Renal plasma flow"
Aop:128	Event:821	KeyEvent	KE	"Decreased, Sodium reabsorption"
Aop:128	Event:813	KeyEvent	KE	"Increased, Serum creatinine"
Aop:128	Event:823	KeyEvent	KE	"Occurrence, Cystic dilatation (renal tubule)"
Aop:128	Event:824	KeyEvent	KE	"Occurrence, Cytoplasmic vacuolization (podocyte)"
Aop:128	Event:818	KeyEvent	KE	"Occurrence, Cytoplasmic vacuolization (Renal tubule)"
Aop:128	Event:825	KeyEvent	KE	"Decreased, Renal ability to dilute urine"
Aop:130	Event:828	MolecularInitiatingEvent	MIE	"Inhibition, Phospholipase A"
Aop:130	Event:829	KeyEvent	KE	"Damage, Lipid bilayer"
Aop:130	Event:831	KeyEvent	KE	"Disturbance, Lysosomal function"
Aop:130	Event:832	KeyEvent	KE	"Injury, Mitochondria"
Aop:130	Event:833	KeyEvent	KE	"Occurrence, Cytoplasmic vacuolization (hepatocyte)"
Aop:130	Event:835	KeyEvent	KE	"Occurrence, Ballooning degeneration (hepatocyte)"
Aop:130	Event:837	KeyEvent	KE	"Occurrence, Cytoplasmic vacuolization (kupffer cell)"
Aop:130	Event:838	KeyEvent	KE	"Induction, Microvesicular fat"
Aop:130	Event:839	KeyEvent	KE	"Formation, Mallory body"
Aop:130	Event:840	AdverseOutcome	AO	"Formation, Liver fibrosis"
Aop:130	Event:836	KeyEvent	KE	"Occurrence, Cytoplasmic vacuolization (Bile duct cell)"
Aop:131	Event:18	MolecularInitiatingEvent	MIE	"Activation, AhR"
Aop:131	Event:844	KeyEvent	KE	"Oxidation, Uroporphyrinogen"
Aop:131	Event:845	KeyEvent	KE	"Inhibition, UROD"
Aop:131	Event:846	KeyEvent	KE	"Accumulation, Highly carboxylated porphyrins"
Aop:131	Event:369	AdverseOutcome	AO	Uroporphyria
Aop:131	Event:850	KeyEvent	KE	"Induction, CYP1A2/CYP1A5"
Aop:134	Event:424	MolecularInitiatingEvent	MIE	"Inhibition, Na+/I- symporter (NIS)"
Aop:134	Event:277	KeyEvent	KE	Decrease of thyroid hormone synthesis
Aop:134	Event:425	KeyEvent	KE	Decrease of Thyroidal iodide
Aop:134	Event:281	KeyEvent	KE	Decrease of thyroxine (T4) in serum
Aop:134	Event:280	KeyEvent	KE	Decrease of thyroxine (T4) in neuronal tissue
Aop:134	Event:756	KeyEvent	KE	"Hippocampal gene expression, Altered "
Aop:134	Event:757	KeyEvent	KE	"Hippocampal anatomy, Altered "
Aop:134	Event:758	KeyEvent	KE	"Hippocampal Physiology, Altered"
Aop:134	Event:402	AdverseOutcome	AO	"Cognitive Function, Decreased "
Aop:134	Event:426	KeyEvent	KE	"Decreased, Thyroxine (T4) in serum"
Aop:136	Event:867	MolecularInitiatingEvent	MIE	"Decrease, Intracellular pH"
Aop:136	Event:868	KeyEvent	KE	"Increase, Tissue Degeneration, Necrosis & Atrophy "
Aop:136	Event:870	KeyEvent	KE	"Increase, Cell Proliferation"
Aop:136	Event:869	KeyEvent	KE	"Increase, Respiratory or Squamous Metaplasia"
Aop:136	Event:768	KeyEvent	KE	"Increase, Cytotoxicity"
Aop:136	Event:872	AdverseOutcome	AO	"Increase, Site of Contact Nasal Tumors"
Aop:136	Event:876	KeyEvent	KE	"Increase, Mutations in Critical Genes"
Aop:138	Event:877	MolecularInitiatingEvent	MIE	"Inhibition, organic anion transporter 1 (OAT1)"
Aop:138	Event:1096	KeyEvent	KE	"Increased, blood uric acid concentration"
Aop:138	Event:1097	KeyEvent	KE	"Occurrence, renal proximal tubular necrosis"
Aop:138	Event:1098	KeyEvent	KE	"Increased, blood potassium concentration"
Aop:138	Event:351	AdverseOutcome	AO	"Increased, Mortality"
Aop:138	Event:361	AdverseOutcome	AO	"Decline, Population"
Aop:138	Event:1102	KeyEvent	KE	"Occurrence, tophi (urate) deposition"
Aop:138	Event:1106	KeyEvent	KE	"Occurrence, cardiac arrhythmia"
Aop:138	Event:1088	KeyEvent	KE	"Increased, Oxidative Stress"
Aop:139	Event:97	MolecularInitiatingEvent	MIE	"Alkylation, DNA"
Aop:139	Event:155	KeyEvent	KE	"N/A, Insufficient or incorrect DNA repair"
Aop:139	Event:185	KeyEvent	KE	"Increase, Mutations"
Aop:139	Event:885	AdverseOutcome	AO	"Increase, Cancer"
Aop:141	Event:155	KeyEvent	KE	"N/A, Insufficient or incorrect DNA repair"
Aop:141	Event:185	KeyEvent	KE	"Increase, Mutations"
Aop:141	Event:885	AdverseOutcome	AO	"Increase, Cancer"
Aop:141	Event:97	MolecularInitiatingEvent	MIE	"Alkylation, DNA"
Aop:144	Event:902	AdverseOutcome	AO	"Inflammation, Liver"
Aop:144	Event:209	KeyEvent	KE	Peptide Oxidation
Aop:144	Event:177	KeyEvent	KE	"N/A, Mitochondrial dysfunction 1"
Aop:144	Event:55	KeyEvent	KE	"N/A, Cell injury/death"
Aop:144	Event:87	KeyEvent	KE	"Release, Cytokine"
Aop:144	Event:898	MolecularInitiatingEvent	MIE	"Disruption, Lysosome"
Aop:144	Event:901	KeyEvent	KE	"Infiltration, Inflammatory cells"
Aop:148	Event:919	KeyEvent	KE	"Occurrence, Transdifferentiation of ciliated epithelial cells"
Aop:148	Event:920	KeyEvent	KE	"Occurrence, Metaplasia of goblet cells"
Aop:148	Event:921	KeyEvent	KE	"Occurrence, Hyperplasia of goblet cells"
Aop:148	Event:923	KeyEvent	KE	"Increase, Proliferation of goblet cells"
Aop:148	Event:924	KeyEvent	KE	"Activation, SP1"
Aop:148	Event:914	KeyEvent	KE	"Decrease, Apoptosis of ciliated epithelial cells"
Aop:148	Event:941	MolecularInitiatingEvent	MIE	"Activation, EGFR"
Aop:148	Event:962	KeyEvent	KE	"Increase, Mucin production"
Aop:148	Event:1250	AdverseOutcome	AO	"Decrease, Lung function"
Aop:148	Event:1251	KeyEvent	KE	"Chronic, Mucus hypersecretion"
Aop:149	Event:209	MolecularInitiatingEvent	MIE	Peptide Oxidation
Aop:149	Event:926	KeyEvent	KE	"Oxidation, Glutathione"
Aop:149	Event:927	KeyEvent	KE	"S-Glutathionylation, eNOS"
Aop:149	Event:935	KeyEvent	KE	"Decrease, GTPCH-1"
Aop:149	Event:934	KeyEvent	KE	"Decrease, Tetrahydrobiopterin"
Aop:149	Event:932	KeyEvent	KE	"Uncoupling, eNOS"
Aop:149	Event:933	KeyEvent	KE	"Depletion, Nitric Oxide"
Aop:149	Event:937	KeyEvent	KE	"impaired, Vasodilation"
Aop:149	Event:951	KeyEvent	KE	"Increase, Vascular Resistance"
Aop:149	Event:952	AdverseOutcome	AO	Hypertension
Aop:149	Event:973	KeyEvent	KE	"Decrease, Akt/eNOS activity"
Aop:150	Event:18	MolecularInitiatingEvent	MIE	"Activation, AhR"
Aop:150	Event:944	KeyEvent	KE	"dimerization, AHR/ARNT"
Aop:150	Event:945	KeyEvent	KE	"reduced dimerization, ARNT/HIF1-alpha"
Aop:150	Event:110	KeyEvent	KE	"Impairment, Endothelial network"
Aop:150	Event:317	KeyEvent	KE	"Altered, Cardiovascular development/function"
Aop:150	Event:947	AdverseOutcome	AO	"Increase, Embryolethality"
Aop:150	Event:948	KeyEvent	KE	"reduced production, VEGF"
Aop:152	Event:957	MolecularInitiatingEvent	MIE	"Binding, Transthyretin in serum"
Aop:152	Event:958	KeyEvent	KE	"Displacement, Serum thyroxine (T4) from transthyretin"
Aop:152	Event:959	KeyEvent	KE	"Increased, Free serum thyroxine (T4)"
Aop:152	Event:960	KeyEvent	KE	"Increased, Uptake of thyroxine into tissue"
Aop:152	Event:961	KeyEvent	KE	"Increased, Clearance of thyroxine from tissues"
Aop:152	Event:281	KeyEvent	KE	Decrease of thyroxine (T4) in serum
Aop:152	Event:280	KeyEvent	KE	Decrease of thyroxine (T4) in neuronal tissue
Aop:152	Event:756	KeyEvent	KE	"Hippocampal gene expression, Altered "
Aop:152	Event:757	KeyEvent	KE	"Hippocampal anatomy, Altered "
Aop:152	Event:758	KeyEvent	KE	"Hippocampal Physiology, Altered"
Aop:152	Event:402	AdverseOutcome	AO	"Cognitive Function, Decreased "
Aop:153	Event:964	MolecularInitiatingEvent	MIE	"Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol"
Aop:153	Event:965	KeyEvent	KE	"reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic production of estradiol in granulosa cells"
Aop:153	Event:966	KeyEvent	KE	"Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulosa cells leading to decreased estradiol in circulation"
Aop:153	Event:967	KeyEvent	KE	"Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation decreases estrogen concentration at hypothalamus"
Aop:153	Event:968	KeyEvent	KE	"Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces kisspeptinergic neuron response "
Aop:153	Event:969	KeyEvent	KE	"Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons "
Aop:153	Event:970	KeyEvent	KE	"Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituitary Gonadotrophs"
Aop:153	Event:971	KeyEvent	KE	"Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required for ovulation "
Aop:153	Event:972	AdverseOutcome	AO	"Decreased fertility, Reduced number of oocytes ovulated "
Aop:154	Event:980	KeyEvent	KE	"Inhibition, Calcineurin Activity"
Aop:154	Event:979	KeyEvent	KE	"Interference, nuclear localization of NFAT"
Aop:154	Event:981	KeyEvent	KE	"Reduction, NFAT complex formation"
Aop:154	Event:984	AdverseOutcome	AO	"Impairment, T-cell dependent antibody response"
Aop:154	Event:1201	MolecularInitiatingEvent	MIE	"Binding, Immunophilins"
Aop:154	Event:1202	KeyEvent	KE	"Suppression, IL-2 and IL-4 production"
Aop:155	Event:1002	MolecularInitiatingEvent	MIE	"Inhibition, Deiodinase 2"
Aop:155	Event:1003	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in serum"
Aop:155	Event:1004	KeyEvent	KE	"Reduced, Posterior swim bladder inflation"
Aop:155	Event:1005	KeyEvent	KE	"Reduced, Swimming performance"
Aop:155	Event:1006	KeyEvent	KE	"Reduced, Young of year survival"
Aop:155	Event:360	AdverseOutcome	AO	"Decrease, Population trajectory"
Aop:155	Event:1007	KeyEvent	KE	"Reduced, Anterior swim bladder inflation"
Aop:155	Event:1008	KeyEvent	KE	"Reduced, Hearing"
Aop:156	Event:1002	MolecularInitiatingEvent	MIE	"Inhibition, Deiodinase 2"
Aop:156	Event:360	AdverseOutcome	AO	"Decrease, Population trajectory"
Aop:156	Event:1003	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in serum"
Aop:156	Event:1007	KeyEvent	KE	"Reduced, Anterior swim bladder inflation"
Aop:156	Event:1008	KeyEvent	KE	"Reduced, Hearing"
Aop:156	Event:1005	KeyEvent	KE	"Reduced, Swimming performance"
Aop:156	Event:1006	KeyEvent	KE	"Reduced, Young of year survival"
Aop:157	Event:1009	MolecularInitiatingEvent	MIE	"Inhibition, Deiodinase 1"
Aop:157	Event:360	AdverseOutcome	AO	"Decrease, Population trajectory"
Aop:157	Event:1003	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in serum"
Aop:157	Event:1004	KeyEvent	KE	"Reduced, Posterior swim bladder inflation"
Aop:157	Event:1005	KeyEvent	KE	"Reduced, Swimming performance"
Aop:157	Event:1006	KeyEvent	KE	"Reduced, Young of year survival"
Aop:157	Event:1007	KeyEvent	KE	"Reduced, Anterior swim bladder inflation"
Aop:157	Event:1008	KeyEvent	KE	"Reduced, Hearing"
Aop:158	Event:1009	MolecularInitiatingEvent	MIE	"Inhibition, Deiodinase 1"
Aop:158	Event:360	AdverseOutcome	AO	"Decrease, Population trajectory"
Aop:158	Event:1003	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in serum"
Aop:158	Event:1007	KeyEvent	KE	"Reduced, Anterior swim bladder inflation"
Aop:158	Event:1008	KeyEvent	KE	"Reduced, Hearing"
Aop:158	Event:1005	KeyEvent	KE	"Reduced, Swimming performance"
Aop:158	Event:1006	KeyEvent	KE	"Reduced, Young of year survival"
Aop:159	Event:279	MolecularInitiatingEvent	MIE	"Thyroperoxidase, Inhibition"
Aop:159	Event:360	AdverseOutcome	AO	"Decrease, Population trajectory"
Aop:159	Event:277	KeyEvent	KE	Decrease of thyroid hormone synthesis
Aop:159	Event:281	KeyEvent	KE	Decrease of thyroxine (T4) in serum
Aop:159	Event:1007	KeyEvent	KE	"Reduced, Anterior swim bladder inflation"
Aop:159	Event:1008	KeyEvent	KE	"Reduced, Hearing"
Aop:159	Event:1005	KeyEvent	KE	"Reduced, Swimming performance"
Aop:159	Event:1006	KeyEvent	KE	"Reduced, Young of year survival"
Aop:160	Event:351	AdverseOutcome	AO	"Increased, Mortality"
Aop:160	Event:762	MolecularInitiatingEvent	MIE	"Activation, ionotropic GABA Receptor chloride channel"
Aop:160	Event:1012	KeyEvent	KE	"Increased, Inhibitory postsynaptic potential"
Aop:160	Event:1014	KeyEvent	KE	"Induction, Somatic muscle paralysis"
Aop:160	Event:761	KeyEvent	KE	"Increased, Chloride conductance"
Aop:160	Event:1015	KeyEvent	KE	"Increased, Neuronal synaptic inhibition"
Aop:160	Event:1016	KeyEvent	KE	"Inhibition, Feeding"
Aop:161	Event:351	AdverseOutcome	AO	"Increased, Mortality"
Aop:161	Event:1015	KeyEvent	KE	"Increased, Neuronal synaptic inhibition"
Aop:161	Event:1012	KeyEvent	KE	"Increased, Inhibitory postsynaptic potential"
Aop:161	Event:1016	KeyEvent	KE	"Inhibition, Feeding"
Aop:161	Event:761	KeyEvent	KE	"Increased, Chloride conductance"
Aop:161	Event:1018	MolecularInitiatingEvent	MIE	"Activation, Glutamate-gated chloride channels"
Aop:161	Event:1019	KeyEvent	KE	"Induction, pharyngeal muscle paralysis"
Aop:162	Event:1020	KeyEvent	KE	"Increased, induction of UDPGT's in liver"
Aop:162	Event:1021	KeyEvent	KE	"Increased, T4/T3 catabolism"
Aop:162	Event:1022	KeyEvent	KE	"Decreased, serum T4/T3"
Aop:162	Event:1023	KeyEvent	KE	"Increased, Thyroid-stimulating hormone (TSH)"
Aop:162	Event:1024	KeyEvent	KE	"Increased, Hypertrophy and proliferation (follicular cell)"
Aop:162	Event:1025	KeyEvent	KE	"Increased, Hyperplasia (follicular cells)"
Aop:162	Event:1026	AdverseOutcome	AO	"Increased Apoptosis, Adenomas/carcinomas (follicular cell)"
Aop:163	Event:1028	MolecularInitiatingEvent	MIE	"Activation of specific nuclear receptors, PPAR-gamma activation"
Aop:163	Event:1029	KeyEvent	KE	"Increased, adipogenesis"
Aop:163	Event:1032	KeyEvent	KE	"Increased, secretion of local growth factors"
Aop:163	Event:1033	KeyEvent	KE	"Increased, proliferation of mesenchymal cells"
Aop:163	Event:1034	KeyEvent	KE	"Increased, IGF-1 (mouse)"
Aop:163	Event:1035	KeyEvent	KE	"Increased, Firbrosarcoma"
Aop:163	Event:1036	KeyEvent	KE	"Increased, liposarcoma"
Aop:163	Event:1037	KeyEvent	KE	"Increased, hemagiosarcoma"
Aop:164	Event:1038	MolecularInitiatingEvent	MIE	"Activation, beta-2 adrenergic receptor"
Aop:164	Event:1039	KeyEvent	KE	"Increased activity, beta-2 adrenergic receptor"
Aop:164	Event:1040	KeyEvent	KE	"relaxation, smooth muscle"
Aop:164	Event:1042	KeyEvent	KE	"Proliferation/Clonal Expansion, smooth muscle"
Aop:164	Event:1043	KeyEvent	KE	"Hypertrophy/hyperplasia, smooth muscle"
Aop:164	Event:1044	AdverseOutcome	AO	"Promotion, mesovarian leiomyomas"
Aop:165	Event:1045	KeyEvent	KE	"Decreased, Ovarian E2"
Aop:165	Event:1046	KeyEvent	KE	"Suppression, Estrogen receptor (ER) activity"
Aop:165	Event:1047	KeyEvent	KE	"Increased, secretion of GnRH from hypothalamus"
Aop:165	Event:1049	KeyEvent	KE	"Increased, secrection of FSH from anterior pituitary"
Aop:165	Event:1050	KeyEvent	KE	"Increased, secretion of LH from anterior pituitary"
Aop:165	Event:1051	KeyEvent	KE	"Hyperplasia, ovarian stromal cells"
Aop:165	Event:1052	KeyEvent	KE	"Hyperplasia, ovarian epithelium"
Aop:165	Event:1053	AdverseOutcome	AO	"Promotion, ovarian adenomas"
Aop:165	Event:1054	AdverseOutcome	AO	"Promotion, ovarian granular cell tumors"
Aop:165	Event:1056	KeyEvent	KE	"Decrease, E2 blood concentrations at hypothalamus"
Aop:166	Event:1057	KeyEvent	KE	"Increased, PPAR-alpha activation"
Aop:166	Event:1058	KeyEvent	KE	"Decreased, bile flow"
Aop:166	Event:1059	KeyEvent	KE	"Increased, cholestasis"
Aop:166	Event:1060	KeyEvent	KE	"Alteration, lipid metabolism"
Aop:166	Event:1061	KeyEvent	KE	"prolonged, elevation of serun CCK"
Aop:166	Event:1062	KeyEvent	KE	"Increased, Cellular proliferation / hyperplasia of acinar cells"
Aop:166	Event:1063	AdverseOutcome	AO	"Increased, Pancreatic acinar tumors"
Aop:167	Event:1064	MolecularInitiatingEvent	MIE	"prepubertal increase, Estrogen receptor (ER) activity"
Aop:167	Event:1065	KeyEvent	KE	"Activation, estrogen receptor alpha"
Aop:167	Event:1066	KeyEvent	KE	"Promotion, SIX-1 postive basal-type progenitor cells"
Aop:167	Event:1067	KeyEvent	KE	"Proliferation/Clonal Expansion, aberrant basal cells"
Aop:167	Event:1068	KeyEvent	KE	"squamous metaplasia, aberrant basal cells"
Aop:167	Event:1069	KeyEvent	KE	"Increased, Hyperplasia (glandular epithelial cells of endometrium)"
Aop:167	Event:1070	AdverseOutcome	AO	"Increased, adenosquamous carcinomas of endometrium"
Aop:168	Event:1071	KeyEvent	KE	"Decreased, GnRH pulsatility/release in hypothalamus"
Aop:168	Event:1072	KeyEvent	KE	"Decreased, LH Surge from anterior pituitary"
Aop:168	Event:1074	KeyEvent	KE	"interruption, Ovulation"
Aop:168	Event:1075	KeyEvent	KE	"prolonged, estrus"
Aop:168	Event:1076	KeyEvent	KE	"Increased, circulating estrogen levels"
Aop:168	Event:1077	KeyEvent	KE	"Increased, prolactin exposure"
Aop:168	Event:1078	KeyEvent	KE	"Hyperplasia, Mammary gland"
Aop:168	Event:1079	AdverseOutcome	AO	"Increased, Adenomas/carcinomas (mammary)"
Aop:168	Event:1080	KeyEvent	KE	"Increased, latency period"
Aop:169	Event:1071	KeyEvent	KE	"Decreased, GnRH pulsatility/release in hypothalamus"
Aop:169	Event:1072	KeyEvent	KE	"Decreased, LH Surge from anterior pituitary"
Aop:169	Event:1075	KeyEvent	KE	"prolonged, estrus"
Aop:169	Event:1074	KeyEvent	KE	"interruption, Ovulation"
Aop:169	Event:1076	KeyEvent	KE	"Increased, circulating estrogen levels"
Aop:169	Event:1081	KeyEvent	KE	"Increased, lactotroph hyperplasia and hypertrophy"
Aop:169	Event:1082	AdverseOutcome	AO	"Increased, adenomas (pituitary)"
Aop:170	Event:1083	KeyEvent	KE	"Decreased, Dopaminergic activity"
Aop:170	Event:1084	KeyEvent	KE	"Increased, prolactin secretion"
Aop:170	Event:1085	KeyEvent	KE	"Increased, hyperplasia (mammary gland)"
Aop:170	Event:1080	KeyEvent	KE	"Increased, latency period"
Aop:170	Event:1079	AdverseOutcome	AO	"Increased, Adenomas/carcinomas (mammary)"
Aop:171	Event:1086	KeyEvent	KE	"persistent, cytotoxicity (pleura or peritoneum)"
Aop:171	Event:1087	KeyEvent	KE	"Increased, inflammation"
Aop:171	Event:1088	KeyEvent	KE	"Increased, Oxidative Stress"
Aop:171	Event:1032	KeyEvent	KE	"Increased, secretion of local growth factors"
Aop:171	Event:1089	KeyEvent	KE	"Increased, Cell Proliferation (mesothelium)"
Aop:171	Event:1090	AdverseOutcome	AO	"Increased, mesotheliomas"
Aop:175	Event:279	MolecularInitiatingEvent	MIE	"Thyroperoxidase, Inhibition"
Aop:175	Event:277	KeyEvent	KE	Decrease of thyroid hormone synthesis
Aop:175	Event:281	KeyEvent	KE	Decrease of thyroxine (T4) in serum
Aop:175	Event:1093	KeyEvent	KE	"Decreased, Thyroxine (T4) in tissues"
Aop:175	Event:1101	AdverseOutcome	AO	"Altered, Amphibian metamorphosis"
Aop:175	Event:1116	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in tissues"
Aop:176	Event:424	MolecularInitiatingEvent	MIE	"Inhibition, Na+/I- symporter (NIS)"
Aop:176	Event:425	KeyEvent	KE	Decrease of Thyroidal iodide
Aop:176	Event:277	KeyEvent	KE	Decrease of thyroid hormone synthesis
Aop:176	Event:281	KeyEvent	KE	Decrease of thyroxine (T4) in serum
Aop:176	Event:1093	KeyEvent	KE	"Decreased, Thyroxine (T4) in tissues"
Aop:176	Event:1101	AdverseOutcome	AO	"Altered, Amphibian metamorphosis"
Aop:176	Event:1116	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in tissues"
Aop:177	Event:1104	KeyEvent	KE	"Decreased, Prostaglandin F2alpha concentration, plasma "
Aop:177	Event:1105	KeyEvent	KE	"Occurrence, renal ischemia"
Aop:177	Event:1097	KeyEvent	KE	"Occurrence, renal proximal tubular necrosis"
Aop:177	Event:1098	KeyEvent	KE	"Increased, blood potassium concentration"
Aop:177	Event:351	AdverseOutcome	AO	"Increased, Mortality"
Aop:177	Event:361	AdverseOutcome	AO	"Decline, Population"
Aop:177	Event:1103	MolecularInitiatingEvent	MIE	"Inhibition, Cyclooxygenase 1 activity"
Aop:177	Event:1106	KeyEvent	KE	"Occurrence, cardiac arrhythmia"
Aop:177	Event:1088	KeyEvent	KE	"Increased, Oxidative Stress"
Aop:177	Event:1096	KeyEvent	KE	"Increased, blood uric acid concentration"
Aop:177	Event:1102	KeyEvent	KE	"Occurrence, tophi (urate) deposition"
Aop:178	Event:559	MolecularInitiatingEvent	MIE	"Activation, Nicotinic acetylcholine receptor"
Aop:178	Event:177	KeyEvent	KE	"N/A, Mitochondrial dysfunction 1"
Aop:178	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:178	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:179	Event:1109	KeyEvent	KE	"Increased, Deformed Wing Virus levels"
Aop:179	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:179	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:180	Event:560	KeyEvent	KE	"Abnormal, Foraging activity and behavior"
Aop:180	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:180	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:181	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:181	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:182	Event:560	KeyEvent	KE	"Abnormal, Foraging activity and behavior"
Aop:182	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:182	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:183	Event:1110	KeyEvent	KE	"Increased, Energetic demands and therefore metabolic stress"
Aop:183	Event:560	KeyEvent	KE	"Abnormal, Foraging activity and behavior"
Aop:183	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:183	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:184	Event:1108	KeyEvent	KE	"Abnormal, Role change within caste"
Aop:184	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:184	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:185	Event:1107	KeyEvent	KE	"Weakened, Colony"
Aop:185	Event:563	AdverseOutcome	AO	"Death/Failure, Colony"
Aop:186	Event:1114	MolecularInitiatingEvent	MIE	"Unknown, MIE"
Aop:186	Event:1115	KeyEvent	KE	"Increased, Reactive oxygen species"
Aop:186	Event:1088	KeyEvent	KE	"Increased, Oxidative Stress"
Aop:186	Event:1097	KeyEvent	KE	"Occurrence, renal proximal tubular necrosis"
Aop:186	Event:1098	KeyEvent	KE	"Increased, blood potassium concentration"
Aop:186	Event:1106	KeyEvent	KE	"Occurrence, cardiac arrhythmia"
Aop:186	Event:351	AdverseOutcome	AO	"Increased, Mortality"
Aop:187	Event:1122	KeyEvent	KE	"Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis  "
Aop:187	Event:1130	KeyEvent	KE	"Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)"
Aop:187	Event:1131	KeyEvent	KE	"Failure in gamma-glutamyl carboxylation of  clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) "
Aop:187	Event:1132	KeyEvent	KE	"Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal"
Aop:187	Event:1133	KeyEvent	KE	"Hemostasis, Depletion from blood of fully functional carboxylated clotting factors"
Aop:187	Event:1134	MolecularInitiatingEvent	MIE	"Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone"
Aop:187	Event:1135	KeyEvent	KE	"Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction"
Aop:187	Event:1136	AdverseOutcome	AO	"Impaired recruitment , Population trajectory"
Aop:187	Event:1138	MolecularInitiatingEvent	MIE	"Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP"
Aop:187	Event:1151	KeyEvent	KE	"Osteoporosis and vascular calcification, Bone deterioration"
Aop:187	Event:1169	MolecularInitiatingEvent	MIE	"Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin"
Aop:188	Event:1152	MolecularInitiatingEvent	MIE	"Inhibition, Iodotyrosine deiodinase (IYD)"
Aop:188	Event:425	KeyEvent	KE	Decrease of Thyroidal iodide
Aop:188	Event:277	KeyEvent	KE	Decrease of thyroid hormone synthesis
Aop:188	Event:426	KeyEvent	KE	"Decreased, Thyroxine (T4) in serum"
Aop:188	Event:1093	KeyEvent	KE	"Decreased, Thyroxine (T4) in tissues"
Aop:188	Event:1116	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in tissues"
Aop:188	Event:1101	AdverseOutcome	AO	"Altered, Amphibian metamorphosis"
Aop:189	Event:1009	MolecularInitiatingEvent	MIE	"Inhibition, Deiodinase 1"
Aop:189	Event:1116	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in tissues"
Aop:189	Event:1003	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in serum"
Aop:189	Event:1101	AdverseOutcome	AO	"Altered, Amphibian metamorphosis"
Aop:190	Event:1002	MolecularInitiatingEvent	MIE	"Inhibition, Deiodinase 2"
Aop:190	Event:1116	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in tissues"
Aop:190	Event:1101	AdverseOutcome	AO	"Altered, Amphibian metamorphosis"
Aop:191	Event:1153	MolecularInitiatingEvent	MIE	"Inhibition, Deiodinase 3"
Aop:191	Event:1154	KeyEvent	KE	"Increased, Triiodothyronine (T3) in tissues"
Aop:191	Event:1101	AdverseOutcome	AO	"Altered, Amphibian metamorphosis"
Aop:192	Event:1155	MolecularInitiatingEvent	MIE	"Inhibition, Pendrin"
Aop:192	Event:277	KeyEvent	KE	Decrease of thyroid hormone synthesis
Aop:192	Event:426	KeyEvent	KE	"Decreased, Thyroxine (T4) in serum"
Aop:192	Event:1093	KeyEvent	KE	"Decreased, Thyroxine (T4) in tissues"
Aop:192	Event:1116	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in tissues"
Aop:192	Event:1101	AdverseOutcome	AO	"Altered, Amphibian metamorphosis"
Aop:193	Event:1156	MolecularInitiatingEvent	MIE	"Inhibition, Dual oxidase"
Aop:193	Event:277	KeyEvent	KE	Decrease of thyroid hormone synthesis
Aop:193	Event:426	KeyEvent	KE	"Decreased, Thyroxine (T4) in serum"
Aop:193	Event:1093	KeyEvent	KE	"Decreased, Thyroxine (T4) in tissues"
Aop:193	Event:1116	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in tissues"
Aop:193	Event:1101	AdverseOutcome	AO	"Altered, Amphibian metamorphosis"
Aop:194	Event:1157	MolecularInitiatingEvent	MIE	"Activation, Hepatic nuclear receptor(s)"
Aop:194	Event:1158	KeyEvent	KE	"Increased, Hepatic thyroid hormone uptake/transport"
Aop:194	Event:295	KeyEvent	KE	"Induction, Upregulation of glucuronyltransferase activity"
Aop:194	Event:401	KeyEvent	KE	"Increase, Biliary excretion TH glucuronide"
Aop:194	Event:281	KeyEvent	KE	Decrease of thyroxine (T4) in serum
Aop:194	Event:1093	KeyEvent	KE	"Decreased, Thyroxine (T4) in tissues"
Aop:194	Event:1116	KeyEvent	KE	"Decreased, Triiodothyronine (T3) in tissues"
Aop:194	Event:1101	AdverseOutcome	AO	"Altered, Amphibian metamorphosis"
Aop:195	Event:619	MolecularInitiatingEvent	MIE	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"
Aop:195	Event:626	KeyEvent	KE	"Increased, serotonin (5-HT) "
Aop:195	Event:1161	KeyEvent	KE	"Increased, oocyte maturation"
Aop:195	Event:1164	AdverseOutcome	AO	"Increased, Population"
Aop:195	Event:1255	KeyEvent	KE	induced spawning
Aop:195	Event:1142	KeyEvent	KE	"Increased, valve movement"
Aop:195	Event:1163	KeyEvent	KE	"Increased, Reproductive Success"
Aop:195	Event:621	KeyEvent	KE	"Increase, cilia movement"
Aop:196	Event:1215	MolecularInitiatingEvent	MIE	"TRPA1 activation, TRPA1 Receptor"
Aop:196	Event:1218	KeyEvent	KE	"Opening of calcium channel, Calcium influx"
Aop:196	Event:1220	KeyEvent	KE	"Excitation, Neuron nerve ending excitation"
Aop:196	Event:1222	KeyEvent	KE	"SP (Substance P) release, Local increase of SP"
Aop:196	Event:1223	AdverseOutcome	AO	Trigeminal and/or vagal nerve excitation
Aop:196	Event:1225	KeyEvent	KE	Immune system inflammation 
Aop:196	Event:1226	AdverseOutcome	AO	"Chronic Cough, Respiratory irritability"
Aop:196	Event:1236	KeyEvent	KE	"Generation of novel epitopes , Antigen presentation"
Aop:196	Event:1237	AdverseOutcome	AO	"Sensitization, Immune system"
Aop:196	Event:1433	KeyEvent	KE	"Increased CGRP, neuronal release of CGRP"
Aop:196	Event:1434	AdverseOutcome	AO	Irritation of nasal mucosa inducing sneeze reflex
Aop:196	Event:1435	KeyEvent	KE	Increased neurokinin A (NKA) by neuronal cells
Aop:197	Event:584	MolecularInitiatingEvent	MIE	"Inhibition, sodium channel"
Aop:197	Event:1176	KeyEvent	KE	"Decreased, sodium conductance 2"
Aop:197	Event:1179	KeyEvent	KE	"Decreased, GABA release"
Aop:200	Event:1181	MolecularInitiatingEvent	MIE	"Activation, Estrogen receptor"
Aop:200	Event:1182	KeyEvent	KE	"Increase, Cell Proliferation (Epithelial Cells)"
Aop:200	Event:1183	KeyEvent	KE	"Decreased, Apoptosis (Epithelial Cells)"
Aop:200	Event:177	KeyEvent	KE	"N/A, Mitochondrial dysfunction 1"
Aop:200	Event:1088	KeyEvent	KE	"Increased, Oxidative Stress"
Aop:200	Event:1187	KeyEvent	KE	"Increased, ER binding to DNA (classical pathway) "
Aop:200	Event:1188	KeyEvent	KE	"Increased, ER binding to T.F. to DNA (non-classical pathway)"
Aop:200	Event:1189	KeyEvent	KE	"Increased, Proliferation (Endothelial cells) "
Aop:200	Event:1190	KeyEvent	KE	"Increased, Migration (Endothelial Cells)"
Aop:200	Event:1191	KeyEvent	KE	"Increased, Non-genomic signaling"
Aop:200	Event:1192	KeyEvent	KE	"Increased, Ductal Hyperplasia "
Aop:200	Event:1193	AdverseOutcome	AO	"N/A, Breast Cancer"
Aop:200	Event:1194	KeyEvent	KE	"Increase, DNA damage"
Aop:200	Event:1195	KeyEvent	KE	"modulation, Extracellular Matrix Composition "
Aop:200	Event:1196	KeyEvent	KE	"Increased, Invasion"
Aop:200	Event:1197	KeyEvent	KE	"Activation, Fibroblasts"
Aop:200	Event:1198	KeyEvent	KE	"Activation, Macrophages"
Aop:200	Event:1213	KeyEvent	KE	"Increased, Angiogenesis"
Aop:200	Event:1239	KeyEvent	KE	"Altered, Gene Expression"
Aop:200	Event:1240	KeyEvent	KE	"Altered, Protein Production"
Aop:200	Event:1241	KeyEvent	KE	"Increased, Motility"
Aop:200	Event:1242	KeyEvent	KE	"Increased, Second Messenger Production"
Aop:201	Event:1205	MolecularInitiatingEvent	MIE	"Activation, Juvenile hormone receptor"
Aop:201	Event:1206	KeyEvent	KE	"Induction, Doublesex1 gene"
Aop:201	Event:1208	AdverseOutcome	AO	"Increased, Male offspring"
Aop:201	Event:1209	KeyEvent	KE	"Induction, Male reproductive tract"
Aop:201	Event:361	AdverseOutcome	AO	"Decline, Population"
Aop:201	Event:1210	AdverseOutcome	AO	"Alteration, Food-web structures"
Aop:202	Event:1252	MolecularInitiatingEvent	MIE	In-utero DNA topoisomerase II “poisons-
Aop:202	Event:1253	KeyEvent	KE	In utero MLL chromosomal translocation
Aop:202	Event:1254	AdverseOutcome	AO	Infant leukaemia
Aop:202	Event:1461	KeyEvent	KE	DNA double-strand break 
Aop:203	Event:619	MolecularInitiatingEvent	MIE	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"
Aop:203	Event:1142	KeyEvent	KE	"Increased, valve movement"
Aop:203	Event:621	KeyEvent	KE	"Increase, cilia movement"
Aop:203	Event:1256	KeyEvent	KE	increased mantel display
Aop:203	Event:1257	KeyEvent	KE	Induced parturition
Aop:203	Event:1141	AdverseOutcome	AO	"Decreased, Reproductive Success"
Aop:203	Event:361	AdverseOutcome	AO	"Decline, Population"
Aop:203	Event:626	KeyEvent	KE	"Increased, serotonin (5-HT) "
Aop:204	Event:619	MolecularInitiatingEvent	MIE	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"
Aop:204	Event:1142	KeyEvent	KE	"Increased, valve movement"
Aop:204	Event:621	KeyEvent	KE	"Increase, cilia movement"
Aop:204	Event:1257	KeyEvent	KE	Induced parturition
Aop:204	Event:1256	KeyEvent	KE	increased mantel display
Aop:204	Event:1163	AdverseOutcome	AO	"Increased, Reproductive Success"
Aop:204	Event:1164	AdverseOutcome	AO	"Increased, Population"
Aop:204	Event:626	KeyEvent	KE	"Increased, serotonin (5-HT) "
Aop:205	Event:1258	MolecularInitiatingEvent	MIE	Decompartmentalization
Aop:205	Event:1260	MolecularInitiatingEvent	MIE	Direct mitochondrial inhibition
Aop:205	Event:1259	MolecularInitiatingEvent	MIE	narcosis
Aop:205	Event:1261	KeyEvent	KE	Mitochondrial impairment
Aop:205	Event:1262	AdverseOutcome	AO	Apoptosis
Aop:205	Event:1263	AdverseOutcome	AO	Necrosis
Aop:206	Event:1270	MolecularInitiatingEvent	MIE	Inactivation of PPARγ
Aop:206	Event:1271	KeyEvent	KE	Activation of TGF-β signaling
Aop:206	Event:1272	KeyEvent	KE	Differentiation of Myofibroblast
Aop:206	Event:1274	KeyEvent	KE	Production of α-smooth muscle actin
Aop:206	Event:1273	KeyEvent	KE	Expression of Collagen
Aop:206	Event:1275	KeyEvent	KE	Collagen Deposition
Aop:206	Event:1276	AdverseOutcome	AO	Lung fibrosis
Aop:207	Event:1174	MolecularInitiatingEvent	MIE	"Activation, NADPH Oxidase"
Aop:207	Event:1277	AdverseOutcome	AO	Reproductive failure
Aop:207	Event:1278	KeyEvent	KE	ROS formation
Aop:207	Event:1279	KeyEvent	KE	"Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK"
Aop:207	Event:1280	KeyEvent	KE	"Activation, HIF-1"
Aop:207	Event:1281	KeyEvent	KE	"Increased, DNA Damage-Repair"
Aop:207	Event:176	KeyEvent	KE	"Damaging, Mitochondria"
Aop:207	Event:1262	KeyEvent	KE	Apoptosis
Aop:208	Event:1282	KeyEvent	KE	"Activation, JAK/STAT pathway"
Aop:208	Event:1283	KeyEvent	KE	"Activation, TGF-beta pathway"
Aop:208	Event:1277	AdverseOutcome	AO	Reproductive failure
Aop:209	Event:1284	KeyEvent	KE	"Up Regulation, SREBF2"
Aop:209	Event:1285	KeyEvent	KE	"Up Regulation, Unsaturated fatty acid"
Aop:209	Event:1286	KeyEvent	KE	"Down Regulation, GSS and GSTs gene"
Aop:209	Event:1287	KeyEvent	KE	Glutathione synthesis
Aop:209	Event:1288	KeyEvent	KE	"Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene"
Aop:209	Event:1289	KeyEvent	KE	Perturbation of cholesterol
Aop:209	Event:1290	KeyEvent	KE	Glutathione homeostasis
Aop:209	Event:1291	AdverseOutcome	AO	Hepatotoxicity
Aop:210	Event:209	KeyEvent	KE	Peptide Oxidation
Aop:210	Event:1292	KeyEvent	KE	"Activation, JNK"
Aop:210	Event:1293	KeyEvent	KE	"Activation, FOXO"
Aop:210	Event:1294	KeyEvent	KE	"Inhibition, Wnt pathway"
Aop:210	Event:1295	KeyEvent	KE	Defect of Embryogenesis
Aop:210	Event:1277	AdverseOutcome	AO	Reproductive failure
Aop:213	Event:1296	KeyEvent	KE	"Increase, insulin"
Aop:213	Event:1297	KeyEvent	KE	"Activation, insulin receptor "
Aop:213	Event:1298	KeyEvent	KE	"Activation, mTORC2"
Aop:213	Event:1299	KeyEvent	KE	"Activation, AKT"
Aop:213	Event:1300	KeyEvent	KE	"Activation, mTORC1"
Aop:213	Event:1301	KeyEvent	KE	"Activation, SREBP-1"
Aop:213	Event:1302	KeyEvent	KE	"Activation, L-FABP "
Aop:213	Event:1305	KeyEvent	KE	"Increase, cytosolic fatty acid"
Aop:213	Event:228	KeyEvent	KE	peroxisome proliferator activated receptor promoter demethylation
Aop:213	Event:258	KeyEvent	KE	"Activation, SCD-1"
Aop:213	Event:1306	KeyEvent	KE	"Increased, lipogenesis"
Aop:213	Event:478	KeyEvent	KE	"Activation, NRF2"
Aop:213	Event:1304	KeyEvent	KE	"Activation, FXR"
Aop:213	Event:480	KeyEvent	KE	"Activation, SHP"
Aop:213	Event:227	KeyEvent	KE	"Activation, PPARα"
Aop:213	Event:1303	KeyEvent	KE	"Activation, HSD17B4"
Aop:213	Event:1307	KeyEvent	KE	"Inhibition, LXR"
Aop:213	Event:468	KeyEvent	KE	"Inhibition, PPAR alpha"
Aop:213	Event:1308	KeyEvent	KE	"Inhibition, LRH-1"
Aop:213	Event:116	KeyEvent	KE	"Activation, FAS"
Aop:213	Event:1309	KeyEvent	KE	"Activation, aPKC"
Aop:213	Event:1310	KeyEvent	KE	"Activation, PI3K"
Aop:213	Event:1311	KeyEvent	KE	"Inhibition, Steatosis"
Aop:213	Event:1312	KeyEvent	KE	"Induction, fatty acid beta-oxidation"
Aop:213	Event:1313	KeyEvent	KE	"Decrease, cytosolic fatty acid"
Aop:213	Event:167	KeyEvent	KE	"Activation, LXR"
Aop:213	Event:1314	KeyEvent	KE	"Activation, LRH-1"
Aop:214	Event:1316	KeyEvent	KE	"Inhibit, serotonin transporter activity"
Aop:214	Event:1317	KeyEvent	KE	"Decreased, serotonin transporter activity"
Aop:214	Event:1318	KeyEvent	KE	"Decreased, extracellular sodium (Na+) "
Aop:214	Event:1319	KeyEvent	KE	"Decreased, extracellular chloride (Cl-)"
Aop:214	Event:1320	KeyEvent	KE	"Increased, extracellular serotonin"
Aop:214	Event:1321	KeyEvent	KE	"Increased, intracellular sodium (Na+)"
Aop:214	Event:1322	KeyEvent	KE	"Increased, intracellular chloride (Cl-)"
Aop:214	Event:1323	KeyEvent	KE	"Decreased, intracellular serotonin"
Aop:214	Event:1324	KeyEvent	KE	"Decreased, packaged serotonin"
Aop:214	Event:1325	KeyEvent	KE	"Decreased, synaptic release"
Aop:214	Event:1326	KeyEvent	KE	"Increased, 5-HT3 (5-hydroxytryptamine)"
Aop:214	Event:1328	KeyEvent	KE	"Inactivated, 5-HTR (serotonin receptors)"
Aop:214	Event:1329	KeyEvent	KE	"Reduce expression, BDNF (Brain-derived neurotrophic factor)"
Aop:214	Event:1330	KeyEvent	KE	"Decreased, neuroplasticity"
Aop:214	Event:1334	KeyEvent	KE	"Increase, cortisone"
Aop:214	Event:122	KeyEvent	KE	"Activation, Glucocorticoid Receptor"
Aop:214	Event:1335	KeyEvent	KE	"Reduced, BDNF (Brain-derived neurotrophic factor)"
Aop:214	Event:1336	KeyEvent	KE	"Activation, 5-HT2A (Serotonin 2A)"
Aop:214	Event:1337	KeyEvent	KE	"Activate, PLC (Phospholipase C)"
Aop:214	Event:1338	KeyEvent	KE	"Increase, inositol triphosphate"
Aop:214	Event:1339	KeyEvent	KE	"Increase, intracellular calcium"
Aop:214	Event:1340	KeyEvent	KE	"Activate, calmodulin"
Aop:214	Event:1341	KeyEvent	KE	"Increase, myosin light chain phosphorylation"
Aop:214	Event:1342	KeyEvent	KE	"Increase, vascular smooth muscle contraction"
Aop:214	Event:1344	AdverseOutcome	AO	"Increased, seizure"
Aop:214	Event:1345	AdverseOutcome	AO	"Increased, agitation"
Aop:214	Event:1346	AdverseOutcome	AO	"Increased, depression"
Aop:214	Event:1343	AdverseOutcome	AO	"Increase, hypertension"
Aop:214	Event:1347	KeyEvent	KE	"Decreased, extracellular serotonin"
Aop:215	Event:1348	AdverseOutcome	AO	"Increase, seizure"
Aop:215	Event:1349	KeyEvent	KE	"Activated, presynaptic neuron 1"
Aop:215	Event:1350	KeyEvent	KE	"Increased, glutamate"
Aop:215	Event:1351	KeyEvent	KE	"Activated, NMDA receptor"
Aop:215	Event:1321	KeyEvent	KE	"Increased, intracellular sodium (Na+)"
Aop:215	Event:1352	KeyEvent	KE	"Activated, voltage-gated sodium channel"
Aop:215	Event:1353	KeyEvent	KE	"Inhibit, voltage-gated sodium channel"
Aop:215	Event:1354	KeyEvent	KE	"Treat, carbamazepine"
Aop:215	Event:1355	KeyEvent	KE	"Activated, membrane depolarization"
Aop:215	Event:1356	KeyEvent	KE	"Inactive, membrane depolarization"
Aop:215	Event:1357	KeyEvent	KE	"Increased, RDX dose"
Aop:215	Event:1358	KeyEvent	KE	"Repress, GABA-A receptor"
Aop:215	Event:1359	KeyEvent	KE	"Activate, GABA-A receptor"
Aop:215	Event:1360	KeyEvent	KE	"Activate, presynaptic neuron 2"
Aop:215	Event:1361	KeyEvent	KE	"Increase, GABA"
Aop:215	Event:1322	KeyEvent	KE	"Increased, intracellular chloride (Cl-)"
Aop:215	Event:1362	AdverseOutcome	AO	"Increased, hippocampal hyperdepolarization"
Aop:215	Event:1363	AdverseOutcome	AO	"Increased, epilepsy"
Aop:216	Event:1194	KeyEvent	KE	"Increase, DNA damage"
Aop:216	Event:1365	KeyEvent	KE	"Increase, Apoptosis"
Aop:216	Event:1366	KeyEvent	KE	"Decrease, Oogenesis"
Aop:216	Event:488	KeyEvent	KE	"Decrease, Ovulation"
Aop:216	Event:1444	KeyEvent	KE	"Increase, Follicular atresia"
Aop:216	Event:330	AdverseOutcome	AO	"Decrease, Fertility"
Aop:216	Event:257	MolecularInitiatingEvent	MIE	"Increase, Reactive oxygen species production"
Aop:217	Event:1367	AdverseOutcome	AO	"Inhibit, gastric ulcer formation"
Aop:217	Event:1368	KeyEvent	KE	"Inhibition, PTGS-1 (Prostaglandin-endoperoxide synthase 1)"
Aop:217	Event:1369	KeyEvent	KE	"Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1)"
Aop:217	Event:1370	KeyEvent	KE	"Activation, PTGS-2 (Prostaglandin-endoperoxide synthase 2)"
Aop:217	Event:1371	KeyEvent	KE	"Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2)"
Aop:217	Event:1372	KeyEvent	KE	"Increase, bicarbonate "
Aop:217	Event:1373	KeyEvent	KE	"Increase, mucous"
Aop:217	Event:1374	KeyEvent	KE	"Increase, mucosal blood flow"
Aop:217	Event:1375	KeyEvent	KE	"Increase, platelet aggregation"
Aop:217	Event:1376	KeyEvent	KE	"Increase, angiogenesis"
Aop:217	Event:1377	KeyEvent	KE	"Decrease, leukocyte adherence"
Aop:217	Event:1378	KeyEvent	KE	"Increase, leukocyte adherence"
Aop:217	Event:1379	KeyEvent	KE	"Activate, leukocyte "
Aop:217	Event:1380	KeyEvent	KE	"Activate, mucosal defense"
Aop:217	Event:1381	KeyEvent	KE	"Increase, surfactant"
Aop:217	Event:1382	KeyEvent	KE	"Decrease, surfactant"
Aop:217	Event:1383	KeyEvent	KE	"Activate, phospholipase"
Aop:217	Event:1384	KeyEvent	KE	"Increase, ammonium (NH4+)"
Aop:217	Event:1385	AdverseOutcome	AO	"Activated, gastric ulcer formation"
Aop:218	Event:1386	MolecularInitiatingEvent	MIE	"CYP7B activity, inhibition"
Aop:218	Event:1387	KeyEvent	KE	"7α-hydroxypregnenolone synthesis in the brain, decreased"
Aop:218	Event:1388	KeyEvent	KE	"Dopamine release in the brain, decreased"
Aop:218	Event:1389	KeyEvent	KE	"Locomotor activity, decreased"
Aop:218	Event:1141	KeyEvent	KE	"Decreased, Reproductive Success"
Aop:218	Event:442	AdverseOutcome	AO	"Decreased, Population trajectory"
Aop:219	Event:1386	MolecularInitiatingEvent	MIE	"CYP7B activity, inhibition"
Aop:219	Event:1387	KeyEvent	KE	"7α-hydroxypregnenolone synthesis in the brain, decreased"
Aop:219	Event:1388	KeyEvent	KE	"Dopamine release in the brain, decreased"
Aop:219	Event:1390	KeyEvent	KE	"Sexual behavior, decreased"
Aop:219	Event:1141	KeyEvent	KE	"Decreased, Reproductive Success"
Aop:219	Event:442	AdverseOutcome	AO	"Decreased, Population trajectory"
Aop:220	Event:1391	MolecularInitiatingEvent	MIE	Activation of Cyp2E1 in the liver
Aop:220	Event:1392	KeyEvent	KE	Oxidative Stress 
Aop:220	Event:1393	KeyEvent	KE	Hepatocytotoxicity
Aop:220	Event:1394	KeyEvent	KE	Hepatocellular Regenerative Proliferation 
Aop:220	Event:1395	AdverseOutcome	AO	Liver Cancer
Aop:221	Event:1335	KeyEvent	KE	"Reduced, BDNF (Brain-derived neurotrophic factor)"
Aop:221	Event:1330	KeyEvent	KE	"Decreased, neuroplasticity"
Aop:221	Event:1328	KeyEvent	KE	"Inactivated, 5-HTR (serotonin receptors)"
Aop:221	Event:1347	KeyEvent	KE	"Decreased, extracellular serotonin"
Aop:221	Event:1325	KeyEvent	KE	"Decreased, synaptic release"
Aop:221	Event:1324	KeyEvent	KE	"Decreased, packaged serotonin"
Aop:221	Event:1323	KeyEvent	KE	"Decreased, intracellular serotonin"
Aop:221	Event:1317	KeyEvent	KE	"Decreased, serotonin transporter activity"
Aop:221	Event:1320	KeyEvent	KE	"Increased, extracellular serotonin"
Aop:221	Event:1346	AdverseOutcome	AO	"Increased, depression"
Aop:221	Event:1329	KeyEvent	KE	"Reduce expression, BDNF (Brain-derived neurotrophic factor)"
Aop:221	Event:1396	MolecularInitiatingEvent	MIE	"Increased, glucocorticoid receptor activity"
Aop:222	Event:1345	AdverseOutcome	AO	"Increased, agitation"
Aop:222	Event:1335	KeyEvent	KE	"Reduced, BDNF (Brain-derived neurotrophic factor)"
Aop:222	Event:1329	KeyEvent	KE	"Reduce expression, BDNF (Brain-derived neurotrophic factor)"
Aop:222	Event:1328	KeyEvent	KE	"Inactivated, 5-HTR (serotonin receptors)"
Aop:222	Event:1330	KeyEvent	KE	"Decreased, neuroplasticity"
Aop:222	Event:1347	KeyEvent	KE	"Decreased, extracellular serotonin"
Aop:222	Event:1317	KeyEvent	KE	"Decreased, serotonin transporter activity"
Aop:222	Event:1320	KeyEvent	KE	"Increased, extracellular serotonin"
Aop:222	Event:1325	KeyEvent	KE	"Decreased, synaptic release"
Aop:222	Event:1324	KeyEvent	KE	"Decreased, packaged serotonin"
Aop:222	Event:1323	KeyEvent	KE	"Decreased, intracellular serotonin"
Aop:222	Event:1396	MolecularInitiatingEvent	MIE	"Increased, glucocorticoid receptor activity"
Aop:223	Event:1320	KeyEvent	KE	"Increased, extracellular serotonin"
Aop:223	Event:1347	KeyEvent	KE	"Decreased, extracellular serotonin"
Aop:223	Event:1344	AdverseOutcome	AO	"Increased, seizure"
Aop:223	Event:1397	MolecularInitiatingEvent	MIE	"Increased, serotonin transporter activity"
Aop:223	Event:1398	KeyEvent	KE	"Increased, intracellular serotonin"
Aop:223	Event:1399	KeyEvent	KE	"Increased, packaged serotonin"
Aop:223	Event:1400	KeyEvent	KE	"Increased, synaptic release"
Aop:223	Event:1401	KeyEvent	KE	"Decreased, 5-HT3"
Aop:224	Event:1346	AdverseOutcome	AO	"Increased, depression"
Aop:224	Event:1320	KeyEvent	KE	"Increased, extracellular serotonin"
Aop:224	Event:1347	KeyEvent	KE	"Decreased, extracellular serotonin"
Aop:224	Event:1397	MolecularInitiatingEvent	MIE	"Increased, serotonin transporter activity"
Aop:224	Event:1398	KeyEvent	KE	"Increased, intracellular serotonin"
Aop:224	Event:1399	KeyEvent	KE	"Increased, packaged serotonin"
Aop:224	Event:1400	KeyEvent	KE	"Increased, synaptic release"
Aop:224	Event:1328	KeyEvent	KE	"Inactivated, 5-HTR (serotonin receptors)"
Aop:224	Event:1329	KeyEvent	KE	"Reduce expression, BDNF (Brain-derived neurotrophic factor)"
Aop:224	Event:1330	KeyEvent	KE	"Decreased, neuroplasticity"
Aop:225	Event:1320	KeyEvent	KE	"Increased, extracellular serotonin"
Aop:225	Event:1347	KeyEvent	KE	"Decreased, extracellular serotonin"
Aop:225	Event:1328	KeyEvent	KE	"Inactivated, 5-HTR (serotonin receptors)"
Aop:225	Event:1329	KeyEvent	KE	"Reduce expression, BDNF (Brain-derived neurotrophic factor)"
Aop:225	Event:1330	KeyEvent	KE	"Decreased, neuroplasticity"
Aop:225	Event:1345	AdverseOutcome	AO	"Increased, agitation"
Aop:225	Event:1397	KeyEvent	KE	"Increased, serotonin transporter activity"
Aop:225	Event:1398	KeyEvent	KE	"Increased, intracellular serotonin"
Aop:225	Event:1399	KeyEvent	KE	"Increased, packaged serotonin"
Aop:225	Event:1400	KeyEvent	KE	"Increased, synaptic release"
Aop:226	Event:1323	KeyEvent	KE	"Decreased, intracellular serotonin"
Aop:226	Event:1324	KeyEvent	KE	"Decreased, packaged serotonin"
Aop:226	Event:1325	KeyEvent	KE	"Decreased, synaptic release"
Aop:226	Event:1320	KeyEvent	KE	"Increased, extracellular serotonin"
Aop:226	Event:1347	KeyEvent	KE	"Decreased, extracellular serotonin"
Aop:226	Event:1336	KeyEvent	KE	"Activation, 5-HT2A (Serotonin 2A)"
Aop:226	Event:1337	KeyEvent	KE	"Activate, PLC (Phospholipase C)"
Aop:226	Event:1338	KeyEvent	KE	"Increase, inositol triphosphate"
Aop:226	Event:1339	KeyEvent	KE	"Increase, intracellular calcium"
Aop:226	Event:1340	KeyEvent	KE	"Activate, calmodulin"
Aop:226	Event:1341	KeyEvent	KE	"Increase, myosin light chain phosphorylation"
Aop:226	Event:1342	KeyEvent	KE	"Increase, vascular smooth muscle contraction"
Aop:226	Event:1343	AdverseOutcome	AO	"Increase, hypertension"
Aop:226	Event:1317	MolecularInitiatingEvent	MIE	"Decreased, serotonin transporter activity"
Aop:227	Event:1402	MolecularInitiatingEvent	MIE	"Reduced, PTGS1 function"
Aop:227	Event:1385	AdverseOutcome	AO	"Activated, gastric ulcer formation"
Aop:227	Event:1403	KeyEvent	KE	"Reduced, platelet aggregation"
Aop:227	Event:1404	KeyEvent	KE	"Decreased, mucosal blood flow"
Aop:227	Event:1405	KeyEvent	KE	"Reduced, mucosal defense"
Aop:227	Event:1406	KeyEvent	KE	"Decreased, mucous"
Aop:227	Event:1407	KeyEvent	KE	"Decreased, bicarbonate"
Aop:228	Event:1408	MolecularInitiatingEvent	MIE	"Reduced, PTGS2 function"
Aop:228	Event:1385	AdverseOutcome	AO	"Activated, gastric ulcer formation"
Aop:228	Event:1409	KeyEvent	KE	"Decreased, angiogenesis"
Aop:228	Event:1410	KeyEvent	KE	"Increased, leukocyte adherence"
Aop:228	Event:1411	KeyEvent	KE	"Increased, leukocyte activation"
Aop:229	Event:1412	MolecularInitiatingEvent	MIE	Helicobacter pylori infection
Aop:229	Event:1384	KeyEvent	KE	"Increase, ammonium (NH4+)"
Aop:229	Event:1383	KeyEvent	KE	"Activate, phospholipase"
Aop:229	Event:1382	KeyEvent	KE	"Decrease, surfactant"
Aop:229	Event:1405	KeyEvent	KE	"Reduced, mucosal defense"
Aop:229	Event:1385	AdverseOutcome	AO	"Activated, gastric ulcer formation"
Aop:230	Event:1349	MolecularInitiatingEvent	MIE	"Activated, presynaptic neuron 1"
Aop:230	Event:1350	KeyEvent	KE	"Increased, glutamate"
Aop:230	Event:1351	KeyEvent	KE	"Activated, NMDA receptor"
Aop:230	Event:1321	KeyEvent	KE	"Increased, intracellular sodium (Na+)"
Aop:230	Event:1352	KeyEvent	KE	"Activated, voltage-gated sodium channel"
Aop:230	Event:1355	KeyEvent	KE	"Activated, membrane depolarization"
Aop:230	Event:1362	KeyEvent	KE	"Increased, hippocampal hyperdepolarization"
Aop:230	Event:1344	KeyEvent	KE	"Increased, seizure"
Aop:230	Event:1363	AdverseOutcome	AO	"Increased, epilepsy"
Aop:230	Event:1354	KeyEvent	KE	"Treat, carbamazepine"
Aop:230	Event:1353	KeyEvent	KE	"Inhibit, voltage-gated sodium channel"
Aop:231	Event:1413	MolecularInitiatingEvent	MIE	"Reduced, presynaptic neuron 2 activity"
Aop:231	Event:1363	AdverseOutcome	AO	"Increased, epilepsy"
Aop:231	Event:1414	KeyEvent	KE	"Decreased, GABA"
Aop:231	Event:1415	KeyEvent	KE	"Reduced, GABA-A receptor activation"
Aop:231	Event:1416	KeyEvent	KE	"Decreased, intracellular chloride"
Aop:231	Event:1355	KeyEvent	KE	"Activated, membrane depolarization"
Aop:231	Event:1362	KeyEvent	KE	"Increased, hippocampal hyperdepolarization"
Aop:231	Event:1344	KeyEvent	KE	"Increased, seizure"
Aop:231	Event:1357	KeyEvent	KE	"Increased, RDX dose"
Aop:232	Event:1417	MolecularInitiatingEvent	MIE	NFE2/Nrf2 repression
Aop:232	Event:1418	AdverseOutcome	AO	"Increased, steatosis"
Aop:232	Event:1419	KeyEvent	KE	"Reduced, FXR activity"
Aop:232	Event:1420	KeyEvent	KE	"Reduced, SHP activity"
Aop:232	Event:1421	KeyEvent	KE	"Activated, LXR"
Aop:232	Event:1422	KeyEvent	KE	"Reduced, PPARalpha"
Aop:232	Event:1423	KeyEvent	KE	"Reduced, HSD17B4 activity"
Aop:232	Event:1424	KeyEvent	KE	"Reduced, fatty acid beta oxidation"
Aop:233	Event:1425	MolecularInitiatingEvent	MIE	Mu Opioid Receptor Agonism
Aop:233	Event:1426	KeyEvent	KE	Release of G Proteins
Aop:233	Event:1427	KeyEvent	KE	Opening of G protein gated inward rectifying K channels
Aop:233	Event:763	KeyEvent	KE	"hyperpolarisation, neuron"
Aop:233	Event:1428	AdverseOutcome	AO	Analgesia
Aop:234	Event:1425	MolecularInitiatingEvent	MIE	Mu Opioid Receptor Agonism
Aop:234	Event:1426	KeyEvent	KE	Release of G Proteins
Aop:234	Event:1429	KeyEvent	KE	Inhibition of N-type Ca ion channels
Aop:234	Event:1430	KeyEvent	KE	Inhibition of neurotransmitter vesicle release
Aop:234	Event:1428	AdverseOutcome	AO	Analgesia
Aop:235	Event:1431	MolecularInitiatingEvent	MIE	Serotonin 1A Receptor Agonism
Aop:235	Event:1426	KeyEvent	KE	Release of G Proteins
Aop:235	Event:1432	AdverseOutcome	AO	Anti-depressant Activity
Aop:235	Event:1427	KeyEvent	KE	Opening of G protein gated inward rectifying K channels
Aop:235	Event:763	KeyEvent	KE	"hyperpolarisation, neuron"
Aop:236	Event:1431	MolecularInitiatingEvent	MIE	Serotonin 1A Receptor Agonism
Aop:236	Event:1426	KeyEvent	KE	Release of G Proteins
Aop:236	Event:1429	KeyEvent	KE	Inhibition of N-type Ca ion channels
Aop:236	Event:1430	KeyEvent	KE	Inhibition of neurotransmitter vesicle release
Aop:236	Event:1432	AdverseOutcome	AO	Anti-depressant Activity
Aop:237	Event:1437	MolecularInitiatingEvent	MIE	Sensing of the stressor by pulmonary cells
Aop:237	Event:1438	KeyEvent	KE	"Increased production of pulmonary, pro-inflammatory cytokines"
Aop:237	Event:1439	KeyEvent	KE	Increased production of pulmonary SAA
Aop:237	Event:1440	KeyEvent	KE	Formation of HDL-SAA
Aop:237	Event:1441	KeyEvent	KE	Increased systemic total cholesterol pool
Aop:237	Event:1442	KeyEvent	KE	Foam cell formation
Aop:237	Event:1443	AdverseOutcome	AO	Plaque progression in arteries
Aop:238	Event:1445	KeyEvent	KE	"Increase, Lipid peroxidation"
Aop:238	Event:1446	KeyEvent	KE	"Increase, Uncoupling of oxidative phosphorylation"
Aop:238	Event:40	KeyEvent	KE	"Decrease, Mitochondrial ATP production"
Aop:238	Event:1366	KeyEvent	KE	"Decrease, Oogenesis"
Aop:238	Event:488	KeyEvent	KE	"Decrease, Ovulation"
Aop:238	Event:330	AdverseOutcome	AO	"Decrease, Fertility"
Aop:238	Event:257	MolecularInitiatingEvent	MIE	"Increase, Reactive oxygen species production"
Aop:241	Event:1456	KeyEvent	KE	"Increase, Differentiation of fibroblasts"
Aop:241	Event:1457	KeyEvent	KE	"Induction, Epithelial Mesenchymal Transition"
Aop:241	Event:68	KeyEvent	KE	"Accumulation, Collagen"
Aop:241	Event:1458	AdverseOutcome	AO	Pulmonary fibrosis
Aop:241	Event:1468	MolecularInitiatingEvent	MIE	"Activation, Latent Transforming Growth Factor Beta 1"
Aop:241	Event:1469	KeyEvent	KE	"Activation, Transforming Growth Factor beta pathway"
Aop:242	Event:1462	MolecularInitiatingEvent	MIE	Thiol group of chemicals interact with sulfuhydryl groups of proteins to form thiol adducts
Aop:242	Event:1463	KeyEvent	KE	Inhibition of lysyl oxidase
Aop:242	Event:1464	KeyEvent	KE	Reduction of collagen crosslinking
Aop:242	Event:1465	KeyEvent	KE	Weak collagen matrix
Aop:242	Event:1466	KeyEvent	KE	Notochord distortion or malformations
Aop:242	Event:1005	KeyEvent	KE	"Reduced, Swimming performance"
Aop:242	Event:1467	AdverseOutcome	AO	"Growth, reduction"
Aop:242	Event:636	AdverseOutcome	AO	"Decreased, survival"
